<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<!-- saved from url=(0052)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/ -->
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
        <!-- AppResources meta begin -->
        <script type="text/javascript">var ncbi_startTime = new Date();</script>
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="">

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="pmc"><meta name="ncbi_pdid" content="article"><meta name="ncbi_acc" content=""><meta name="ncbi_domain" content="bmcpsyc"><meta name="ncbi_report" content="record"><meta name="ncbi_type" content="fulltext"><meta name="ncbi_objectid" content=""><meta name="ncbi_pcid" content="/articles/PMC1156914/"><meta name="ncbi_app" content="pmc">
        <!-- Logger end -->
        
        <title>Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="./PMC1156914_files/jig.min.css"><script type="text/javascript" src="./PMC1156914_files/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"><link rel="canonical" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="BMC Psychiatry"><meta name="citation_title" content="Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics"><meta name="citation_authors" content="Douglas Faries, Haya Ascher-Svanum, Baojin Zhu, Christoph Correll, John Kane"><meta name="citation_date" content="2005"><meta name="citation_volume" content="5"><meta name="citation_firstpage" content="26"><meta name="citation_doi" content="10.1186/1471-244X-5-26"><meta name="citation_abstract_html_url" content="/pmc/articles/PMC1156914/?report=abstract"><meta name="citation_pmid" content="15921508"><meta name="DC.Title" content="Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics"><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="BioMed Central"><meta name="DC.Contributor" content="Douglas Faries"><meta name="DC.Contributor" content="Haya Ascher-Svanum"><meta name="DC.Contributor" content="Baojin Zhu"><meta name="DC.Contributor" content="Christoph Correll"><meta name="DC.Contributor" content="John Kane"><meta name="DC.Date" content="2005"><meta name="DC.Identifier" content="10.1186/1471-244X-5-26"><meta name="DC.Language" content="en"><meta property="og:title" content="Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics"><meta property="og:type" content="article"><meta property="og:description" content="Antipsychotic monotherapy is recognized as the treatment of choice for patients with schizophrenia. Simultaneous treatment with multiple antipsychotics (polypharmacy) is suggested by some expert consensus guidelines as the last resort after exhausting ..."><meta property="og:url" content="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/"><meta property="og:site_name" content="PubMed Central (PMC)"><meta property="og:image" content="http://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ncbi"><link rel="stylesheet" href="./PMC1156914_files/pmc.min.css" type="text/css"><link rel="stylesheet" href="./PMC1156914_files/pmc_extras_prnt.min.css" type="text/css" media="print"><script type="text/javascript" src="./PMC1156914_files/common.min.js">//</script><script type="text/javascript" src="./PMC1156914_files/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:&#39;/pmc/utils/ctxp/&#39;"><script type="text/javascript" src="./PMC1156914_files/jquery.citationexporter.js">//</script><link rel="stylesheet" href="./PMC1156914_files/citationexporter.css" type="text/css"><script type="text/javascript" src="./PMC1156914_files/MathJax.js"></script><script type="text/javascript" src="./PMC1156914_files/large-obj-scrollbars.min.js"></script><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-bmcpsyc.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
      </style><link rel="alternate" type="application/epub+zip" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/epub/"><link rel="alternate" type="application/pdf" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/pdf/1471-244X-5-26.pdf">

        <!-- Page meta end -->
    <link rel="shortcut icon" href="http://www.ncbi.nlm.nih.gov/favicon.ico"><meta name="ncbi_phid" content="F4FC7CE576C2648100000000000A774F"><link type="text/css" rel="stylesheet" href="./PMC1156914_files/3855312.css"><link type="text/css" rel="stylesheet" href="./PMC1156914_files/3929378.css" media="print"><style type="text/css" media="print">.print-log { position:absolute;left:-10000px;top:auto;width:1px;height:1px;overflow:hidden; }.print-log li { list-style-image: url('http://www.ncbi.nlm.nih.gov/stat?jsevent=print&ncbi_app=pmc&ncbi_db=pmc&ncbi_pcid=%2Farticles%2FPMC1156914%2F&ncbi_pdid=article&ncbi_phid=F4FC7CE576C2648100000000000A774F'); }</style><style type="text/css">.print-log { position:absolute;left:-10000px;top:auto;width:1px;height:1px;overflow:hidden; }</style><style type="text/css">.MathJax_Preview {color: #888}
#MathJax_Message {position: fixed; left: 1em; bottom: 1.5em; background-color: #E6E6E6; border: 1px solid #959595; margin: 0px; padding: 2px 8px; z-index: 102; color: black; font-size: 80%; width: auto; white-space: nowrap}
#MathJax_MSIE_Frame {position: absolute; top: 0; left: 0; width: 0px; z-index: 101; border: 0px; margin: 0px; padding: 0px}
.MathJax_Error {color: #CC0000; font-style: italic}
</style><style type="text/css">.MathJax_Hover_Frame {border-radius: .25em; -webkit-border-radius: .25em; -moz-border-radius: .25em; -khtml-border-radius: .25em; box-shadow: 0px 0px 15px #83A; -webkit-box-shadow: 0px 0px 15px #83A; -moz-box-shadow: 0px 0px 15px #83A; -khtml-box-shadow: 0px 0px 15px #83A; border: 1px solid #A6D ! important; display: inline-block; position: absolute}
.MathJax_Menu_Button .MathJax_Hover_Arrow {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 4px; -webkit-border-radius: 4px; -moz-border-radius: 4px; -khtml-border-radius: 4px; font-family: 'Courier New',Courier; font-size: 9px; color: #F0F0F0}
.MathJax_Menu_Button .MathJax_Hover_Arrow span {display: block; background-color: #AAA; border: 1px solid; border-radius: 3px; line-height: 0; padding: 4px}
.MathJax_Hover_Arrow:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_Hover_Arrow:hover span {background-color: #CCC!important}
</style><style type="text/css">#MathJax_Zoom {position: absolute; background-color: #F0F0F0; overflow: auto; display: block; z-index: 301; padding: .5em; border: 1px solid black; margin: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; -webkit-box-sizing: content-box; -moz-box-sizing: content-box; box-sizing: content-box; box-shadow: 5px 5px 15px #AAAAAA; -webkit-box-shadow: 5px 5px 15px #AAAAAA; -moz-box-shadow: 5px 5px 15px #AAAAAA; -khtml-box-shadow: 5px 5px 15px #AAAAAA; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_ZoomOverlay {position: absolute; left: 0; top: 0; z-index: 300; display: inline-block; width: 100%; height: 100%; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
#MathJax_ZoomFrame {position: relative; display: inline-block; height: 0; width: 0}
#MathJax_ZoomEventTrap {position: absolute; left: 0; top: 0; z-index: 302; display: inline-block; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
</style><style type="text/css">#MathJax_About {position: fixed; left: 50%; width: auto; text-align: center; border: 3px outset; padding: 1em 2em; background-color: #DDDDDD; color: black; cursor: default; font-family: message-box; font-size: 120%; font-style: normal; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 15px; -webkit-border-radius: 15px; -moz-border-radius: 15px; -khtml-border-radius: 15px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_About.MathJax_MousePost {outline: none}
.MathJax_Menu {position: absolute; background-color: white; color: black; width: auto; padding: 5px 0px; border: 1px solid #CCCCCC; margin: 0; cursor: default; font: menu; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; -khtml-border-radius: 5px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
.MathJax_MenuItem {padding: 1px 2em; background: transparent}
.MathJax_MenuArrow {position: absolute; right: .5em; padding-top: .25em; color: #666666; font-size: .75em}
.MathJax_MenuActive .MathJax_MenuArrow {color: white}
.MathJax_MenuArrow.RTL {left: .5em; right: auto}
.MathJax_MenuCheck {position: absolute; left: .7em}
.MathJax_MenuCheck.RTL {right: .7em; left: auto}
.MathJax_MenuRadioCheck {position: absolute; left: .7em}
.MathJax_MenuRadioCheck.RTL {right: .7em; left: auto}
.MathJax_MenuLabel {padding: 1px 2em 3px 1.33em; font-style: italic}
.MathJax_MenuRule {border-top: 1px solid #DDDDDD; margin: 4px 3px}
.MathJax_MenuDisabled {color: GrayText}
.MathJax_MenuActive {background-color: #606872; color: white}
.MathJax_MenuDisabled:focus, .MathJax_MenuLabel:focus {background-color: #E8E8E8}
.MathJax_ContextMenu:focus {outline: none}
.MathJax_ContextMenu .MathJax_MenuItem:focus {outline: none}
#MathJax_AboutClose {top: .2em; right: .2em}
.MathJax_Menu .MathJax_MenuClose {top: -10px; left: -10px}
.MathJax_MenuClose {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; font-family: 'Courier New',Courier; font-size: 24px; color: #F0F0F0}
.MathJax_MenuClose span {display: block; background-color: #AAA; border: 1.5px solid; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; line-height: 0; padding: 8px 0 6px}
.MathJax_MenuClose:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_MenuClose:hover span {background-color: #CCC!important}
.MathJax_MenuClose:hover:focus {outline: none}
</style></head>
    <body class="article" id="ui-jig-5"><div id="MathJax_Message" style="display: none;"></div>
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	&lt;p class="nojs"&gt;
	&lt;strong&gt;Warning:&lt;/strong&gt;
	The NCBI web site requires JavaScript to function. 
	&lt;a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank"&gt;more...&lt;/a&gt;
	&lt;/p&gt;
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list ui-ncbibasicmenu orientation_hort" id="navcontent" role="menubar"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt" role="presentation"><a class="ui-ncbimenu-link-first" href="http://www.ncbi.nlm.nih.gov/" role="menuitem" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="./PMC1156914_files/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo"></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="http://www.ncbi.nlm.nih.gov/static/header_footer_ajax/submenu/#resources" tabindex="-1" role="menuitem">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="http://www.ncbi.nlm.nih.gov/static/header_footer_ajax/submenu/#howto" tabindex="-1" role="menuitem">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="http://www.ncbi.nlm.nih.gov/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="http://www.ncbi.nlm.nih.gov/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="http://www.ncbi.nlm.nih.gov/account/?back_url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1156914%2F" id="sign_in">Sign in to NCBI</a><a href="http://www.ncbi.nlm.nih.gov/account/signout/?back_url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1156914%2F" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo">
  <h1 class="img_logo"><a href="http://www.ncbi.nlm.nih.gov/pmc/" class="pmc_logo offscreen">PMC</a></h1>
  <div class="NLMLogo">
    <a href="http://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>
    <br>
    <a href="http://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>
  </div>
</div>
    <div class="search"><form method="get" action="http://www.ncbi.nlm.nih.gov/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="pubmed" class="last">PubMed</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="clone">Clone</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="nucest">EST</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="nucgss">GSS</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="pubmedhealth">PubMed Health</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbook">ToolKitBook</option><option value="toolkitbookgh">ToolKitBookgh</option><option value="unigene">UniGene</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><div class="ui-ncbiclearbutton-wrap box-shadow"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" config="dictionary:&#39;pmc-search-autocomplete&#39;,disableUrl:&#39;NcbiSearchBarAutoComplCtrl&#39;" autocomplete="off" data-sbconfig="ds:&#39;no&#39;,pjs:&#39;no&#39;,afs:&#39;yes&#39;" aria-haspopup="true" aria-autocomplete="list" role="textbox"><a class="reset" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#" style="visibility: hidden;"><img src="./PMC1156914_files/clear.png" alt="Clear input"></a></div></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/limits/">Limits</a>
                    </li><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/advanced/">Advanced</a>
                    </li><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/journals/">Journal list</a>
                    </li><li class="help">
                        <a target="_blank" href="http://www.ncbi.nlm.nih.gov/books/NBK3825/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <div class="container">
    <div id="maincontent" class="content eight_col col">
        <div class="navlink-box">
            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="http://www.ncbi.nlm.nih.gov/pmc/journals/" class="navlink">Journal List</a></li><li class="archive-page"><a class="navlink" href="http://www.ncbi.nlm.nih.gov/pmc/journals/62/">BMC Psychiatry</a></li><li class="issue-page"><a class="navlink" href="http://www.ncbi.nlm.nih.gov/pmc/issues/18178/">v.5; 2005</a></li><li class="accid">PMC1156914</li></ul>
        </div>

        <!-- Journal banner -->
        <div class="pmc-page-banner whole_rhythm"><div><img src="./PMC1156914_files/logo-bmcpsyc.png" alt="Logo of bmcpsyc" usemap="#logo-imagemap"><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="0,0,162,75" alt="BioMed Central" title="BioMed Central" href="http://www.biomedcentral.com/" ref="reftype=publisher&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext"><area shape="rect" coords="247,59,296,75" alt="search" title="search" href="http://www.biomedcentral.com/bmcphychiatry/search" ref="reftype=publisher&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext"><area shape="rect" coords="301,59,405,75" alt="submit a manuscript" title="submit a manuscript" href="http://www.biomedcentral.com/bmcphychiatry/manuscript" ref="reftype=publisher&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext"><area shape="rect" coords="415,59,458,75" alt="register" title="register" href="http://www.biomedcentral.com/bmcphychiatry/register" ref="reftype=publisher&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext"><area shape="rect" coords="185,59,244,75" alt="this article" title="this article" href="http://dx.doi.org/10.1186/1471-244X-5-26" ref="reftype=publisher&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CBanner&amp;TO=Content%20Provider%7CArticle%7CFullText&amp;rendering-type=normal" target="pmc_ext"><area shape="rect" coords="0,0,480,75" alt="BMC Psychiatry" title="BMC Psychiatry" href="http://www.biomedcentral.com/bmcphychiatry" ref="reftype=publisher&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal" target="pmc_ext"></map></div> </div>
        
        <!--component id='MainPortlet' label='search-reference'/-->
        
        <!-- Book content -->
        <div class="">
            
        
            
            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: [&#39;h2&#39;], headingExclude: &#39;:hidden&#39;" id="ui-jig-1"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="small"><div class="inline_block eight_col va_top"><div><div><span class="cit">BMC Psychiatry. 2005; 5: 26. </span></div><div><span class="fm-vol-iss-date">Published online 2005 May 27. </span>  <span class="doi">doi:&nbsp; <a href="http://dx.doi.org/10.1186%2F1471-244X-5-26" target="pmc_ext" ref="reftype=other&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">10.1186/1471-244X-5-26</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC1156914</span></div></div></div></div></div><h1 class="content-title">Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Faries%20D%5Bauth%5D">Douglas Faries</a>,<sup>1</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Ascher-Svanum%20H%5Bauth%5D">Haya Ascher-Svanum</a>,<sup><img src="./PMC1156914_files/corrauth.gif" alt="corresponding author"></sup><sup>1</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Zhu%20B%5Bauth%5D">Baojin Zhu</a>,<sup>1</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Correll%20C%5Bauth%5D">Christoph Correll</a>,<sup>2</sup> and  <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Kane%20J%5Bauth%5D">John Kane</a><sup>2</sup></div></div><div class="fm-panel small half_rhythm"><div class="fm-authors-info fm-panel hide half_rhythm" id="id942278_ai" style="display:none"><div class="fm-affl" lang="en"><sup>1</sup>Outcomes Research, Eli Lilly and Company, Indianapolis, Indiana, USA</div><div class="fm-affl" lang="en"><sup>2</sup>Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, New York, USA</div><div><sup><img src="./PMC1156914_files/corrauth.gif" alt="corresponding author"></sup>Corresponding author.</div><div><span class="contrib-email" id="A1">Douglas Faries: <a href="mailto:dev@null" data-email="moc.yllil@seiraf.d" class="oemail">moc.yllil@seiraf.d</a>; </span> <span class="contrib-email" id="A2">Haya Ascher-Svanum: <a href="mailto:dev@null" data-email="moc.yllil@ayah" class="oemail">moc.yllil@ayah</a>; </span> <span class="contrib-email" id="A3">Baojin Zhu: <a href="mailto:dev@null" data-email="moc.yllil@z.nijoab" class="oemail">moc.yllil@z.nijoab</a>; </span> <span class="contrib-email" id="A4">Christoph Correll: <a href="mailto:dev@null" data-email="ude.jil@llerrocc" class="oemail">ude.jil@llerrocc</a>; </span> <span class="contrib-email" id="A5">John Kane: <a href="mailto:dev@null" data-email="UDE.JIL@ivaihcSS" class="oemail">UDE.JIL@ivaihcSS</a></span> </div></div><div class="togglers"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#" class="pmctoggle" rid="id942278_ai">Author information <span>►</span></a> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#" class="pmctoggle" rid="id942278_an">Article notes <span>►</span></a> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#" class="pmctoggle" rid="id942278_cpl">Copyright and License information <span>►</span></a></div><div class="fm-article-notes fm-panel hide half_rhythm" id="id942278_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2005 Jan 13; Accepted 2005 May 27.</div></div><div class="fm-cpl-info fm-panel hide half_rhythm" id="id942278_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="http://www.ncbi.nlm.nih.gov/pmc/about/copyright.html">Copyright</a>  © 2005 Faries et al; licensee BioMed Central Ltd.</div><div class="fm-copyright half_rhythm"><p id="__p1">This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<a href="http://creativecommons.org/licenses/by/2.0" ref="reftype=extlink&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CFront%20Matter&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="pmc_ext">http://creativecommons.org/licenses/by/2.0</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></div></div></div><div class="links-box fm-panel whole_rhythm"><div class="small"><div>This article has been <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="__abstractid871854" lang="en" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-7"><span role="menubar"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#" title="Go to other sections in this page" role="menuitem" aria-expanded="false" aria-haspopup="true" id="ui-jig-8">Go to:</a></span></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__abstractid871854title">Abstract</h2><!--article-meta--><div><div id="__sec1" class="sec sec-first"><h3>Background</h3><p id="__p2" class="p p-first-last">Antipsychotic monotherapy is recognized as the treatment of choice for patients with schizophrenia. Simultaneous treatment with multiple antipsychotics (polypharmacy) is suggested by some expert consensus guidelines as the last resort after exhausting monotherapy alternatives. This study assessed the annual rate and duration of antipsychotic monotherapy and its inverse, antipsychotic polypharmacy, among schizophrenia patients initiated on commonly used atypical antipsychotic medications.</p></div><div id="__sec2" class="sec"><h3>Methods</h3><p id="__p3" class="p p-first-last">Data were drawn from a large prospective naturalistic study of patients treated for schizophrenia-spectrum disorders, conducted 7/1997–9/2003. Analyses focused on patients (N = 796) who were initiated during the study on olanzapine (N = 405), quetiapine (N = 115), or risperidone (N = 276). The percentage of patients with monotherapy on the index antipsychotic over the 1-year post initiation, and the cumulative number of days on monotherapy were calculated for all patients and for each of the 3 atypical antipsychotic treatment groups. Analyses employed repeated measures generalized linear models and non-parametric bootstrap re-sampling, controlling for patient characteristics.</p></div><div id="__sec3" class="sec"><h3>Results</h3><p id="__p4" class="p p-first-last">During the 1-year period, only a third (35.7%) of the patients were treated predominately with monotherapy (&gt;300 days). Most patients (57.7%) had at least one prolonged period of antipsychotic polypharmacy (&gt;60 consecutive days). Patients averaged 195.5 days on monotherapy, 155.7 days on polypharmacy, and 13.9 days without antipsychotic therapy. Olanzapine-initiated patients were significantly more likely to be on monotherapy with the initiating antipsychotic during the 1-year post initiation compared to risperidone (p = .043) or quetiapine (p = .002). The number of monotherapy days was significantly greater for olanzapine than quetiapine (p &lt; .001), but not for olanzapine versus risperidone, or for risperidone versus quetiapine-initiated patients.</p></div><div id="__sec4" class="sec sec-last"><h3>Conclusion</h3><p id="__p5" class="p p-first-last">Despite guidelines recommending the use of polypharmacy only as a last resort, the use of antipsychotic polypharmacy for prolonged periods is very common during the treatment of schizophrenia patients in usual care settings. In addition, in this non-randomized naturalistic observational study, the most commonly used atypical antipsychotics significantly differed on the rate and duration of antipsychotic monotherapy. Reasons for and the impact of the predominant use of polypharmacy will require further study.</p></div></div></div><div id="__sec5" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-9"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-10">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec5title">Background</h2><p id="__p6" class="p p-first">Guidelines for treating patients with schizophrenia [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B1" rid="B1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308127252" role="button" aria-expanded="false" aria-haspopup="true">1</a>-<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B5" rid="B5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308127246" role="button" aria-expanded="false" aria-haspopup="true">5</a>] have long recognized antipsychotics as the core treatment modality and have consistently recommended antipsychotic monotherapy as the treatment of choice. Although expert consensus guidelines do not advocate antipsychotic polypharmacy, some [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B4" rid="B4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028182" role="button" aria-expanded="false" aria-haspopup="true">4</a>] suggest antipsychotic polypharmacy as the last resort after having exhausted prior monotherapy alternatives. Only one of the consensus guidelines [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B5" rid="B5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308127254" role="button" aria-expanded="false" aria-haspopup="true">5</a>] offers guidance on the duration of antipsychotic polypharmacy, which is recommended when switching from one antipsychotic to another (cross titration or overlap and taper) and for not longer than 60 days.</p><p id="__p7">Monotherapy is recognized as the preferred mode of treatment because it allows clinicians to accurately evaluate the patient's response to a new course of treatment [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B6" rid="B6" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">6</a>]. Monotherapy permits documenting patient's response to an adequate trial of each medication, helping to reduce the complexity of the medication regimen, reducing the risk of adverse events, and making it easier to assess and manage future symptom exacerbations [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B7" rid="B7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028158" role="button" aria-expanded="false" aria-haspopup="true">7</a>].</p><p id="__p8">Despite consistent recommendations of antipsychotic monotherapy, polypharmacy is widespread in the treatment of schizophrenia [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B7" rid="B7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028163" role="button" aria-expanded="false" aria-haspopup="true">7</a>-<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B15" rid="B15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028159" role="button" aria-expanded="false" aria-haspopup="true">15</a>]. The proliferation of antipsychotic polypharmacy is likely driven by increased availability of pharmacologically diverse atypical antipsychotics that augment an extensive armamentarium of typical antipsychotics. Generally, the concurrent use of more than one antipsychotic, particularly of typical and atypical agents, was reported to vary from 13% to 60%, depending on the population studied, the year when the study has been conducted, the study method, the type of treatment site, and the duration of the study period [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B8" rid="B8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028143" role="button" aria-expanded="false" aria-haspopup="true">8</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B9" rid="B9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028174" role="button" aria-expanded="false" aria-haspopup="true">9</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B14" rid="B14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028166" role="button" aria-expanded="false" aria-haspopup="true">14</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B16" rid="B16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028138" role="button" aria-expanded="false" aria-haspopup="true">16</a>-<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B19" rid="B19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028141" role="button" aria-expanded="false" aria-haspopup="true">19</a>].</p><p id="__p9">The body of evidence supporting the benefits of antipsychotic polypharmacy is limited [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B7" rid="B7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028130" role="button" aria-expanded="false" aria-haspopup="true">7</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B8" rid="B8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028162" role="button" aria-expanded="false" aria-haspopup="true">8</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B20" rid="B20" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">20</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B21" rid="B21" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028167" role="button" aria-expanded="false" aria-haspopup="true">21</a>] and is in contrast to the extensive and compelling body of evidence supporting monotherapy with atypical antipsychotics [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B6" rid="B6" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">6</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B7" rid="B7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028178" role="button" aria-expanded="false" aria-haspopup="true">7</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B9" rid="B9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028151" role="button" aria-expanded="false" aria-haspopup="true">9</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B11" rid="B11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028160" role="button" aria-expanded="false" aria-haspopup="true">11</a>-<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B13" rid="B13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028133" role="button" aria-expanded="false" aria-haspopup="true">13</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B22" rid="B22" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">22</a>-<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B24" rid="B24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028175" role="button" aria-expanded="false" aria-haspopup="true">24</a>].</p><p id="__p10">Antipsychotic polypharmacy was reported to increase the risk of medication-related adverse events and of drug-drug interactions, to increase the need for additional medications to treat emerging side-effects, to decrease adherence with medication due to increased treatment complexity, confounding clinicians' ability to discern helpful from unhelpful medications, and to increase cost of care [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B7" rid="B7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028139" role="button" aria-expanded="false" aria-haspopup="true">7</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B10" rid="B10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308127248" role="button" aria-expanded="false" aria-haspopup="true">10</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B25" rid="B25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028153" role="button" aria-expanded="false" aria-haspopup="true">25</a>]. A recent case-control study of psychiatric inpatients demonstrated that short-term treatment with antipsychotic polytherapy was associated with major increases in drug exposure, in adverse events, and in hospitalized duration but with no apparent clinical benefit [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B16" rid="B16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028181" role="button" aria-expanded="false" aria-haspopup="true">16</a>].</p><p id="__p11">Antipsychotic polypharmacy appears to be used for various reasons [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B7" rid="B7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028157" role="button" aria-expanded="false" aria-haspopup="true">7</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B11" rid="B11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028136" role="button" aria-expanded="false" aria-haspopup="true">11</a>], with the one cited most often being the wish to bolster medication effectiveness in treating patients with refractory psychotic symptoms, mood symptoms, or behavioral problems [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B9" rid="B9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028144" role="button" aria-expanded="false" aria-haspopup="true">9</a>]. It is, however, unclear if antipsychotic polypharmacy is associated with specific atypical antipsychotics more often than with others.</p><p id="__p12">The body of research on differential monotherapy or polypharmacy among atypical agents is sparse [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B8" rid="B8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028145" role="button" aria-expanded="false" aria-haspopup="true">8</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B26" rid="B26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308127247" role="button" aria-expanded="false" aria-haspopup="true">26</a>-<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B30" rid="B30" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">30</a>]. It is unclear if risperidone and quetiapine-treated patients differ on monotherapy parameters. Most previous studies reported higher monotherapy or lower polypharmacy rates for olanzapine compared to risperidone [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B18" rid="B18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028176" role="button" aria-expanded="false" aria-haspopup="true">18</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B19" rid="B19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028148" role="button" aria-expanded="false" aria-haspopup="true">19</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B28" rid="B28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028179" role="button" aria-expanded="false" aria-haspopup="true">28</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B29" rid="B29" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">29</a>], and compared to quetiapine-treated patients [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B25" rid="B25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028180" role="button" aria-expanded="false" aria-haspopup="true">25</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B27" rid="B27" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">27</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B30" rid="B30" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">30</a>], whereas olanzapine and risperidone-treated patients were not found to significantly differ on polypharmacy rates in three studies [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B25" rid="B25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028177" role="button" aria-expanded="false" aria-haspopup="true">25</a>-<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B27" rid="B27" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">27</a>]. The reasons for the inconsistent findings are unclear but may stem from methodological issues, including lack of complete information about the use of depot antipsychotics, about use of medications during psychiatric hospitalizations, and inadequate control for potential selection effects, which arise from clinicians' tendency to tailor treatment regimens to patients' illness profiles and previous treatment patterns.</p><p id="__p13" class="p p-last">This study expanded on prior research by using comprehensive medication data from a large prospective multi-site naturalistic study of patients treated for schizophrenia-spectrum disorders in the United States to assess the annual rate and duration of monotherapy, and its inverse, antipsychotic polypharmacy. We also focused on patients initiated on commonly used atypical antipsychotics – olanzapine, quetiapine, or risperidone – and compared their rates and duration of monotherapy during the year following initiation on the antipsychotic medication.</p></div><div id="__sec6" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-11"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-12">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec6title">Methods</h2><div id="__sec7" class="sec sec-first"><h3>Data source</h3><p id="__p14" class="p p-first">This study used data of the U.S. Schizophrenia Care and Assessment Program (US-SCAP), a large (N = 2327) non-randomized, naturalistic, 3-year prospective multi-site study conducted between 7/1997 and 9/2003. The goal of US-SCAP was to understand the treatment of patients with schizophrenia in usual care settings. Approximately 400 patients at each of the study's six regional sites were enrolled. All participants were diagnosed with schizophrenia, schizoaffective, or schizophreniform disorders based on DSM-IV criteria, and were at least 18 years of age. Patients were excluded if they were unable to provide informed consent or had participated in a clinical drug trial within 30 days prior to enrollment.</p><p id="__p15">In order to reduce selection bias, outpatients were randomly selected from site medical information rosters of active clients. Inpatients were sequential admissions. Of 3332 patients who met inclusion criteria, 765 (23.0%) refused, and 240 (7.2%) were not enrolled for other reasons. Most enrollees competed 1 year of follow-up (78.1%), with fewer participants completing 2 years (69.6%), and 3 years (65.2%). Of the 2327 enrollees, 21.2% were hospitalized at enrollment or during the 6 months prior to enrollment, and 36.2% were hospitalized in the year prior to enrollment.</p><p id="__p16">Participants were enrolled from six states (California, Colorado, Connecticut, Florida, Maryland, and North Carolina) and represented treatment in diverse systems of care including community mental health centers, university health care systems, the Department of Veterans Affairs Health Services (VA), and community and state hospitals. Institutional Review Board (IRB) approval was received at each regional site and informed consent was received from all participants.</p><p id="__p17">At enrollment, almost all participants (94.7%) were treated with at least one antipsychotic medication, including oral typical (36.7%), oral atypical (58.1%), and depot typical antipsychotics (19.6%). Medication changes during the study period, including initiations and discontinuations, if any, were based on physicians' decisions as they occur in usual care. Further details about US-SCAP are available elsewhere [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B31" rid="B31" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308127253" role="button" aria-expanded="false" aria-haspopup="true">31</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B32" rid="B32" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028169" role="button" aria-expanded="false" aria-haspopup="true">32</a>].</p><p id="__p18" class="p p-last">The current study included data of US-SCAP participants who were initiated on one of three commonly used atypical antipsychotics – olanzapine, quetiapine, or risperidone, in regular oral formulation. Participants were defined as initiators if they were not prescribed the index antipsychotic for at least 60 days prior to initiation, had at least 2 months of treatment data available prior to initiation of the index antipsychotic, and had at least 12 months of follow-up information in the study post initiation. Inclusion of data for the 2 months prior to initiation allowed for identification of variables on which the treatment groups differed at the time of initiation. Further, because this study aimed to assess use of antipsychotics over a 1-year period, availability of a 12-month follow-up period was necessary. Note that patients were not excluded from the analysis if they stopped their antipsychotic therapy – only if they discontinued or completed the study within less than 12 months post initiation. Some patients may have met inclusion criteria for being an initiator of more than one medication throughout the 3-year period. Such patients were considered to be initiators of the first antipsychotic medication they initiated in the study.</p></div><div id="__sec8" class="sec"><h3>Outcome measures</h3><p id="__p19" class="p p-first">Medical records provided information about prescribed psychiatric medications and were systematically abstracted for the 6 months prior to enrollment and for each 6-month interval thereafter. Patients were queried about the use of medications and other mental health resources outside those received at their regular treatment site. When this occurred, systematic efforts were made to abstract out-of-site medical records.</p><p id="__p20">On a daily basis, monotherapy (polypharmacy) was defined as the occurrence of one (more than one) ongoing antipsychotic medication prescription. Predominant use of monotherapy (polypharmacy) was defined as the use of monotherapy (polypharmacy) for &gt; 300 days out of the year. Substantial monotherapy (polypharmacy) use was defined as the use of monotherapy (polypharmacy) for &gt; 60 to ≤ 300 days out of the year. Consistent with expert consensus guidelines [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B5" rid="B5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308127250" role="button" aria-expanded="false" aria-haspopup="true">5</a>], prolonged polypharmacy was defined as a period of more than 60 <em>consecutive </em>days of polypharmacy.</p><p id="__p21">Two parameters of antipsychotic monotherapy were used as the outcome measures for initiating treatment group comparisons (olanzapine, quetiapine, or risperidone): (a) the percentage of patients on antipsychotic monotherapy with the index atypical antipsychotic over the 1-year post initiation, and (b) the cumulative number of days of antipsychotic monotherapy.</p><p id="__p22" class="p p-last">Participants were assessed with standard psychiatric measures at enrollment and at 12-month intervals thereafter. These measures were not administered, however, at the time of initiation or discontinuation of any medication. Consequently, these variables were not used in this study. Furthermore, the study did not assess reasons for medication initiation or discontinuation, thus eliminating the ability to evaluate the reasons for any medication changes.</p></div><div id="__sec9" class="sec sec-last"><h3>Statistical methods</h3><p id="__p23" class="p p-first">Summary statistics were used to quantify monotherapy/polypharmacy use at initiation on the medication and across the 1-year period post initiation for all patients (N = 796). This included summarizing the distribution of durations on monotherapy/polypharmacy as well as classification of patients based on predominant, substantial monotherapy/polypharmacy definitions and the prolonged use of polypharmacy.</p><p id="__p24">To assess differences in the use of monotherapy between the treatment groups, two statistical approaches were utilized. First, treatment group differences in the percentage of patients on monotherapy each day over the 1-year following initiation were assessed using a repeated measures general linear model (GEE, Generalized Estimating Equations) [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B33" rid="B33" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">33</a>] with an exchangeable correlation matrix. GEE models are widely used for analyzing longitudinal binary data as they provide consistent parameter estimates and account for the correlation of responses within patients over time. The model consisted of terms for treatment, time, treatment by time interaction, and a set of a priori determined covariates discussed below. Second, treatment group differences in the mean number of days of monotherapy over the 1-year following initiation were assessed. As the distribution of the number of days was non-normal – with a high percentage of patients with zero days, a non-parametric propensity score adjusted bootstrap re-sampling approach was utilized [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B34" rid="B34" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">34</a>].</p><p id="__p25">In all treatment comparisons, differences were adjusted for a set of available covariates selected <em>a priori</em>. These covariates were selected based on the expectations that they may be associated with monotherapy use. Some clinical variables that were collected at 1-year intervals in this study were not used as covariates because they were not collected at the point of initiation or discontinuation of any medication. Thus, the covariates used for adjustment in this study included available socio-demographic and medication history variables: age, gender, ethnicity, illness duration, monotherapy status at initiation (yes/no), investigational site, time, time by treatment interaction, and the following variables based on the 2 months prior to initiation of the index antipsychotic: any psychiatric hospitalization, number of days of antipsychotic monotherapy, and any use of: typical antipsychotics, atypical antipsychotics, antiparkinsonian agents, antidepressants, anti-anxiety medications, sleep agents, mood stabilizers, and typical antipsychotics in depot formulation.</p><p id="__p26" class="p p-last">No adjustment for multiple comparisons was performed as we considered the repeated measures GEE model the primary analysis and the monotherapy duration analysis as a secondary analysis to assess the robustness of the primary results.</p></div></div><div id="__sec10" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-13"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-14">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec10title">Results</h2><div id="__sec11" class="sec sec-first"><h3>Patient characteristics</h3><p id="__p27" class="p p-first">Table <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/table/T1/" target="true" class="fig-table-link table figpopup" rid-figpopup="T1" rid-ob="ob-T1" co-legend-rid=""><span style="position: relative;text-decoration:none;">​<span class="figpopup-sensitive-area" style="left: -2.5em;">Table1</span></span><span>1</span></a> summarizes the socio-demographic characteristics and medication history for the patient population. The sample (N = 796) included patients who were initiated during the study on olanzapine (N = 405), quetiapine (N = 115), or risperidone (N = 276). While similar in many aspects, the treatment groups differed on several characteristics – most notably the percentage of patients on antipsychotic polypharmacy at initiation, which was highest among quetiapine-treated patients and lowest for the risperidone treatment group. During the 2 months prior to initiation on the index antipsychotic, a greater percentage of quetiapine-treated patients were treated with atypical antipsychotics and mood stabilizers; a greater percentage of olanzapine-treated patients were treated with typical antipsychotics in both oral and depot formulations; risperidone patients had fewer antipsychotic monotherapy days. Further, the quetiapine treatment group had least males, the lowest illness duration, and fewest patients with substance use disorders.</p><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="T1"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/table/T1/" target="table" rid-ob="ob-T1" rid-figpopup="T1" class="table img_link icnblk_img figpopup"><img alt="Table 1" title="Table 1" class="small-thumb" src="./PMC1156914_files/saved_resource" src-large="/pmc/articles/PMC1156914/table/T1/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/table/T1/" target="table" rid-figpopup="T1" rid-ob="ob-T1">Table 1</a></div><!--caption a4--><div><span>Baseline characteristics of patients initiated on olanzapine, risperidone, and quetiapine</span></div></div></div></div><div id="__sec12" class="sec"><h3>Medication dose</h3><p id="__p34" class="p p-first">The dosing of each antipsychotic during the year post initiation, at initiation and at endpoint, and by monotherapy versus polypharmacy status at initiation is presented in Table <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/table/T2/" target="true" class="fig-table-link table figpopup" rid-figpopup="T2" rid-ob="ob-T2" co-legend-rid=""><span style="position: relative;text-decoration:none;">​<span class="figpopup-sensitive-area" style="left: -2.5em;">Table2.</span></span><span>2</span></a>. Mean doses were higher at endpoint than at initiation and were within the package insert guidelines for the vast majority of the patients. In addition, the mean doses were higher for those on monotherapy than polypharmacy at initiation, but this was not always found at endpoint.</p><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="T2"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/table/T2/" target="table" rid-ob="ob-T2" rid-figpopup="T2" class="table img_link icnblk_img figpopup"><img alt="Table 2" title="Table 2" class="small-thumb" src="./PMC1156914_files/saved_resource(1)" src-large="/pmc/articles/PMC1156914/table/T2/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/table/T2/" target="table" rid-figpopup="T2" rid-ob="ob-T2">Table 2</a></div><!--caption a4--><div><span>Daily Dose (mg/day) of Index Atypical Antipsychotic: During the 1-Year Post Initiation, at Initiation, and at Endpoint</span></div></div></div></div><div id="__sec13" class="sec"><h3>Overall rates and duration of antipsychotic monotherapy/polypharmacy</h3><p id="__p37" class="p p-first">Approximately one-third (34%) of the 796 patients were initiated on antipsychotic monotherapy with the index antipsychotic. Conversely, most patients (66%) received another antipsychotic, or polypharmacy, at the time of initiation. Only 30% of the polypharmacy-initiated patients were deemed to be in the process of medication change because their polypharmacy ceased within 60 days following initiation on the atypical agent.</p><p id="__p38">The distribution of monotherapy and polypharmacy treatment categories during the 1-year period (Figure <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/figure/F1/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="F1" rid-ob="ob-F1" co-legend-rid="lgnd_F1"><span style="position: relative;text-decoration:none;">​<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure1)</span></span><span>1</span></a>) indicates that about a third (35.7%) of the patients were treated predominately with monotherapy (&gt;300 days), 26.9% were treated predominately with polypharmacy (&gt;300 days), 30.2% had a mix of both substantial monotherapy and polypharmacy treatment periods (61–300 days of each), and 0.6% were not treated with any antipsychotic for more than 300 days. A small proportion of the patients (6.6%) had periods without antipsychotic medications along with substantial treatment periods with either monotherapy or polypharmacy (61–300 days).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="F1" co-legend-rid="lgnd_F1"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1"><img src="./PMC1156914_files/1471-244X-5-26-1.gif" class="small-thumb" alt="Figure 1" title="Figure 1" src-large="/pmc/articles/PMC1156914/bin/1471-244X-5-26-1.jpg"></a><div class="icnblk_cntnt" id="lgnd_F1"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/figure/F1/" target="figure" rid-figpopup="F1" rid-ob="ob-F1">Figure 1</a></div><!--caption a4--><div><span>Percent of patients in each monotherapy/polypharmacy treatment category. Abbreviations: Mono, monotherapy; Poly, polytherapy; No AP, no antipsychotic treatment. Definitions: Monotherapy: Predominant antipsychotic monotherapy (&gt; 300 days); Polypharmacy:</span> <strong>...</strong></div></div></div><p id="__p40" class="p">Overall, patients averaged 195.5 days on monotherapy (54% of the year), 155.7 days on polypharmacy (43% of the year), and 13.9 days without antipsychotic therapy (3% of the year). The distribution of the average number of polypharmacy days for each patient over the 1-year period (Figure <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/figure/F2/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="F2" rid-ob="ob-F2" co-legend-rid="lgnd_F2"><span style="position: relative;text-decoration:none;">​<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure2)</span></span><span>2</span></a>) indicates that 40.6% had polypharmacy for less than 60 days. In fact, most patients (57.7%) had at least one prolonged period of antipsychotic polypharmacy (longer than 60 consecutive days).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="F2" co-legend-rid="lgnd_F2"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2"><img src="./PMC1156914_files/1471-244X-5-26-2.gif" class="small-thumb" alt="Figure 2" title="Figure 2" src-large="/pmc/articles/PMC1156914/bin/1471-244X-5-26-2.jpg"></a><div class="icnblk_cntnt" id="lgnd_F2"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/figure/F2/" target="figure" rid-figpopup="F2" rid-ob="ob-F2">Figure 2</a></div><!--caption a4--><div><span>Percent of patients with antipsychotic polypharmacy during the 1-year period by duration category.</span></div></div></div></div><div id="__sec14" class="sec sec-last"><h3>Specific rates and duration of monotherapy/polypharmacy</h3><p id="__p42" class="p p-first">A significantly greater percentage of olanzapine-treated patients were on antipsychotic monotherapy during the 1-year period compared to risperidone and to quetiapine. Olanzapine-treated patients were 2.08 times more likely to be on monotherapy than quetiapine (Odds Ratio (OR) = 2.08, 95% Confidence Interval (CI), 1.30–3.31, p = .002), and 1.36 times more likely to be on monotherapy than risperidone (OR = 1.36, 95%CI, 1.01–1.84, p = .043). Differences between risperidone and quetiapine initiators showed a trend toward significance (OR = 1.53, 95% CI, 0.94–2.47, p = .085).</p><p id="__p43">The percentages of patients on antipsychotic monotherapy during every week in the 1-year following initiation for each treatment group are provided in Figure <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/figure/F3/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="F3" rid-ob="ob-F3" co-legend-rid="lgnd_F3"><span style="position: relative;text-decoration:none;">​<span class="figpopup-sensitive-area" style="left: -3em;">Figure3.</span></span><span>3</span></a>. Due to the strong influence of monotherapy status at initiation on later monotherapy status, and the treatment differences in monotherapy status at initiation, results are also shown stratified by monotherapy status at initiation in Figure <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/figure/F4/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="F4" rid-ob="ob-F4" co-legend-rid="lgnd_F4"><span style="position: relative;text-decoration:none;">​<span class="figpopup-sensitive-area" style="left: -3em;">Figure4</span></span><span>4</span></a>.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="F3" co-legend-rid="lgnd_F3"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3"><img src="./PMC1156914_files/1471-244X-5-26-3.gif" class="small-thumb" alt="Figure 3" title="Figure 3" src-large="/pmc/articles/PMC1156914/bin/1471-244X-5-26-3.jpg"></a><div class="icnblk_cntnt" id="lgnd_F3"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/figure/F3/" target="figure" rid-figpopup="F3" rid-ob="ob-F3">Figure 3</a></div><!--caption a4--><div><span>Percent of patients on monotherapy during the 1-year following initiation on the atypical antipsychotic medication. Using a GEE (generalized estimating equations) repeated measures binary data model, pair-wise comparisons found a significantly higher</span> <strong>...</strong></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="F4" co-legend-rid="lgnd_F4"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/figure/F4/" target="figure" rid-figpopup="F4" rid-ob="ob-F4"><img src="./PMC1156914_files/1471-244X-5-26-4.gif" class="small-thumb" alt="Figure 4" title="Figure 4" src-large="/pmc/articles/PMC1156914/bin/1471-244X-5-26-4.jpg"></a><div class="icnblk_cntnt" id="lgnd_F4"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/figure/F4/" target="figure" rid-figpopup="F4" rid-ob="ob-F4">Figure 4</a></div><!--caption a4--><div><span>Percent of patients on monotherapy after initiation on antipsychotic polypharmacy or antipsychotic monotherapy. Abbreviations: OLZ, olanzapine; Poly, polypharmacy at initiation; QUE, quetiapine; RIS, risperidone; Mono, monotherapy at initiation</span></div></div></div><p id="__p46" class="p">The observed mean number of monotherapy days on the initiating antipsychotic for olanzapine, quetiapine, and risperidone are presented in Table <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/table/T3/" target="true" class="fig-table-link table figpopup" rid-figpopup="T3" rid-ob="ob-T3" co-legend-rid=""><span style="position: relative;text-decoration:none;">​<span class="figpopup-sensitive-area" style="left: -2.5em;">Table3</span></span><span>3</span></a> for patients initiating on monotherapy and for patients initiating on polypharmacy. For monotherapy or polypharmacy initiators, patients on olanzapine had a greater number of days of monotherapy on the initiating medication while quetiapine initiators had the fewest. Using a propensity score bootstrap analysis, pair-wise comparisons found a significantly longer duration on monotherapy for olanzapine compared to quetiapine (p &lt; .001) and a trend toward longer duration for risperidone initiators as compared to quetiapine (p = .052). The difference between olanzapine and risperidone was not statistically significant.</p><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="T3"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/table/T3/" target="table" rid-ob="ob-T3" rid-figpopup="T3" class="table img_link icnblk_img figpopup"><img alt="Table 3" title="Table 3" class="small-thumb" src="./PMC1156914_files/saved_resource(2)" src-large="/pmc/articles/PMC1156914/table/T3/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/table/T3/" target="table" rid-figpopup="T3" rid-ob="ob-T3">Table 3</a></div><!--caption a4--><div><span>Number of monotherapy days on the initiating antipsychotic during the 1-year post initiation</span></div></div></div></div></div><div id="__sec15" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-15"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-16">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec15title">Discussion</h2><p id="__p49" class="p p-first">In this large prospective naturalistic study of patients with schizophrenia, antipsychotic polypharmacy was found to be highly prevalent and to be of prolonged duration. Overall, most patients (57.7%) had at least one period of antipsychotic polypharmacy longer than 60 consecutive days, and only a third (35.7%) of the patients were treated predominately with monotherapy. More specifically, two thirds (66%) of the patients were treated with another antipsychotic at the time of initiation on the atypical agent, a practice that could have signaled a medication change process. However, most of these patients continued on antipsychotic polypharmacy for a substantial duration and only a small proportion of those patients (30%) were deemed to have gone through medication changes as polypharmacy ceased within the first 60 days after medication initiation. Findings suggest that for the majority of patients, polypharmacy is a prolonged and deliberate treatment choice rather than an interim, brief, or unintentional practice.</p><p id="__p50">A third (34%) of the patients were not receiving another antipsychotic at the time of initiation on the studied atypical medications (olanzapine, quetiapine, and risperidone). These monotherapy-initiated patients continued on monotherapy for only about a third of the year post initiation, and at the end of that year, more than 50% of them were no longer receiving monotherapy with the initiating antipsychotic. Further attesting to the pervasive practice of antipsychotic polypharmacy is the finding that over 40% of all patients had no days of monotherapy with the initiating atypical antipsychotics during the 1-year treatment period. On the average, patients were treated with monotherapy for 54% of the year, with polypharmacy for 43% of the year, and without antipsychotic therapy for 3% of the year.</p><p id="__p51">While polypharmacy was found to be prevalent in this patient population, the question of generalizability remains. However, a goal in designing the US-SCAP study was to generate a sample of patients representative of those treated in usual care. Participants in this large prospective naturalistic study were treated for schizophrenia at large public health care delivery systems in the United States, and were enrolled from multiple sites across six states. The patients were randomly identified from active client rosters at each site and only then approached about enrollment in the study. In addition, there were few exclusion criteria that would restrict the patient population.</p><p id="__p52">This study provided a 1-year longitudinal perspective on the rate and duration of polypharmacy following initiation on the index antipsychotic whereas most previous studies assessed polypharmacy during shorter time periods, such as a 2-month window [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B15" rid="B15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028132" role="button" aria-expanded="false" aria-haspopup="true">15</a>], or during inpatient hospitalization [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B16" rid="B16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028134" role="button" aria-expanded="false" aria-haspopup="true">16</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B19" rid="B19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028165" role="button" aria-expanded="false" aria-haspopup="true">19</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B25" rid="B25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028168" role="button" aria-expanded="false" aria-haspopup="true">25</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B26" rid="B26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308127249" role="button" aria-expanded="false" aria-haspopup="true">26</a>]. Generally, the larger is the studied time window, the higher is the likelihood of finding polypharmacy. Another major difference is the age of the data because polypharmacy has increased over the years. Studies using data from the earlier years after the introduction of the atypical antipsychotics [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B10" rid="B10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_308127251" role="button" aria-expanded="false" aria-haspopup="true">10</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B14" rid="B14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028146" role="button" aria-expanded="false" aria-haspopup="true">14</a>] tend to report lower prevalence rates of antipsychotic polypharmacy, whereas studies using more recent data reported higher polypharmacy rates [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B8" rid="B8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028131" role="button" aria-expanded="false" aria-haspopup="true">8</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B15" rid="B15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028150" role="button" aria-expanded="false" aria-haspopup="true">15</a>]. The complexity involved in comparing findings across studies is further compounded by variations in the definition of polypharmacy. Although most studies defined polypharmacy as any time with more than one antipsychotic [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B15" rid="B15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028147" role="button" aria-expanded="false" aria-haspopup="true">15</a>], others have set specific time requirements, such as at least 14 days of concurrent antipsychotic use [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B8" rid="B8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028154" role="button" aria-expanded="false" aria-haspopup="true">8</a>]. Other differences in study methods can generate different results. While the current study followed patients after their initiation on certain antipsychotic medications, other studies used a cross sectional method, assessing the prevalence of polypharmacy at a given time window, without using time of initiation on the studied antipsychotic medications as the reference point. While cross sectional designs provide important information about prevailing practices at a given time window, the cross sectional method is not well suited for comparisons between antipsychotic treatment groups. When the date of initiation on the antipsychotic is not used as a starting point, treatment group differences may be obscured by differential duration on the medication prior to the studied time window, data that are not included in cross sectional designs.</p><p id="__p53">This study also found significant differences in monotherapy and polypharmacy between the most commonly prescribed atypical antipsychotic medications. Patients initiated on olanzapine were significantly more likely to be on monotherapy compared to quetiapine (rate and duration) or risperidone-initiated patients (rate only) during the 1-year post treatment initiation. The current findings appear consistent with several previous studies in which olanzapine-treated patients were found to have significantly higher rate of monotherapy compared to risperidone [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B18" rid="B18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028171" role="button" aria-expanded="false" aria-haspopup="true">18</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B19" rid="B19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028135" role="button" aria-expanded="false" aria-haspopup="true">19</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B28" rid="B28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028137" role="button" aria-expanded="false" aria-haspopup="true">28</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B29" rid="B29" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">29</a>], and compared to quetiapine-treated patients [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B25" rid="B25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028156" role="button" aria-expanded="false" aria-haspopup="true">25</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B27" rid="B27" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">27</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B30" rid="B30" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">30</a>], with the quetiapine treatment group being the least likely to be treated monotherapy [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B8" rid="B8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028142" role="button" aria-expanded="false" aria-haspopup="true">8</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B27" rid="B27" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">27</a>]. Findings are particularly congruent with those reported in a study of medication patterns in the Michigan Medicaid database [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B28" rid="B28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028183" role="button" aria-expanded="false" aria-haspopup="true">28</a>], in which the proportion of schizophrenia patients treated with olanzapine monotherapy remained relatively steady over the first 3 months of treatment while the proportion of patients receiving risperidone monotherapy decreased over time.</p><p id="__p54">The present study helps demonstrate the dynamic and complex nature of medication management of patients with schizophrenia in usual clinical practice [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B14" rid="B14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028164" role="button" aria-expanded="false" aria-haspopup="true">14</a>]. In addition to providing new information on the rate of monotherapy during treatment with various atypical agents, this study further contributes to the literature by providing a longitudinal perspective on the duration of monotherapy/polypharmacy following treatment initiation. The strengths of this study appear to lie in its large representative and diverse sample, the ability to provide comparative data on a number of commonly used atypical antipsychotics, the availability of comprehensive medication information about use of antipsychotics in depot formulation and about antipsychotics used during hospitalizations (types of data often absent in claims databases), and notably, the ability to generalize the findings to patients treated at large public systems of health care across the United States.</p><p id="__p55">This study also has its limitations. First is the use of naturalistic observational data to compare antipsychotic treatment groups, because observed group differences in rates or duration of monotherapy could result from pre-existing differences between the treatment groups rather than differences in medication choice. Physicians tend to select treatments for different types of patients and illness profiles, a practice that may lead to lack of comparability between the treatment groups at initiation. Analyses that do not appropriately control for such differences can be biased, and one can never be certain that all important group differences have been controlled for statistically. Indeed, in this study differences were observed between groups at initiation. Although differences in several available pre-existing patient and treatment characteristics were controlled for in the analysis, it is possible that other pre-existing group differences were present. For instance, the design of this study did not include assessment of symptom severity or substance use at the time of initiation on the index antipsychotic. Thus, differences in symptom severity or substance use at initiation could not be controlled for.</p><p id="__p56">Another study limitation is lack of information about reasons for initiating antipsychotic medication changes or the specific treatment indications. This type of information was not assessed in US-SCAP but could be valuable in discerning whether there is a link between treatment effectiveness and antipsychotic monotherapy (or polypharmacy). Treatment indication is also important because some antipsychotics, particularly quetiapine in low doses, may have been used to treat insomnia rather than core symptoms of schizophrenia. Although some have speculated that higher doses of quetiapine produce better outcome, the available data [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B35" rid="B35" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028140" role="button" aria-expanded="false" aria-haspopup="true">35</a>] do not support this. Davis and Chen [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B35" rid="B35" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028149" role="button" aria-expanded="false" aria-haspopup="true">35</a>] observed, however, "the sponsor of quetiapine has 2 studies of dose response, one nearing completion, and the other just beginning, so more information will be available in the future". They also noted "the fact that individuals do clinically improve at higher doses in open studies does not prove that the higher dose was responsible, as such improvement might reflect the passage of time, augmenting drugs, or other confounding factors."</p><p id="__p57">Further, this study did not control for potential "sponsorship" bias that could have influenced clinicians' prescription rates and duration of monotherapy in favor of the sponsor's antipsychotic medication (in this case, olanzapine). Although we cannot completely rule out this possibility, sponsor bias is unlikely to have played a role in this study because the current findings are highly consistent with findings of other studies conducted by independent researchers who used non-industry-sponsored data such as Medicaid claims database [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B18" rid="B18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028170" role="button" aria-expanded="false" aria-haspopup="true">18</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B19" rid="B19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028184" role="button" aria-expanded="false" aria-haspopup="true">19</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B28" rid="B28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028152" role="button" aria-expanded="false" aria-haspopup="true">28</a>,<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B29" rid="B29" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">29</a>]. Additional support for the validity of our findings and their freedom from sponsorship bias comes from a recent double-blind randomized study conducted by the sponsors of risperidone [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B35" rid="B35" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_135028173" role="button" aria-expanded="false" aria-haspopup="true">35</a>], comparing risperidone and quetiapine on the rate of antipsychotic polypharmacy. That short term trial found the relative risk (quetiapine vs. risperidone) of using antipsychotic polypharmacy to be higher for quetiapine compared to risperidone (odds ratio 1.90, 95% CI, 1.29–2.80, p = 0.001), a finding similar to that in our observational study, in which the odds ratio for antipsychotic polypharmacy of quetiapine vs. risperidone was 1.53 (95% CI 0.94–2.47, p = 0.085).</p><p id="__p58" class="p p-last">This study also did not present information about concomitant use of psychotropic medications other than antipsychotics, thus providing a partial understanding of the full range of psychotropic polypharmacy that takes place in usual practice. This is a complex phenomenone that will benefit from a separate and detailed study. We, however, cognizant of the potential role of prior concomitant psychotropic medications and used five types of psychotropics (antidepressants, anti-anxiety, antiparkinsonian, mood stabilizers, and sleep agents) in the analyses. Because prior use of concomitant psychotropics is highly correlated with continued use of these concomitant medications post initiation of the new antipsychotic regimen, we opted to include patients' prior concomitant medication as covariates in the analyses. The correlations between concomitant psychotropic medication use prior to initiation on the index drug and its concomitant use post initiation on the antipsychotic were consistently high, ranging from .65 to .81 (r = .81 for antidepressants, r = .80 for anti-anxiety agents, r = .73 for antiparkinsonians, r = .81 for mood stabilizers, and r = .65 for sleep agents). These correlations suggest that the bigger factor in the use of concomitant psychotropic medications post antipsychotic initiation is likely patients' prior medication history and not the antipsychotic monotherapy/polypharmacy status. Generally, the mean daily total number of concomitant psychotropic medications was higher for patients on antipsychotic polypharmacy (1.56) than for patients on antipsychotic monotherapy (1.24). Lastly, this study did not address the potential impact of polypharmacy on the total cost of antipsychotic treatment, or on patients' clinical outcomes, an area of investigation that will require further study.</p></div><div id="__sec16" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-17"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-18">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec16title">Conclusion</h2><p id="__p59" class="p p-first-last">This large prospective study of treatment in usual care settings demonstrated that antipsychotic medication management of schizophrenia patients is a complex process characterized by prevalent and prolonged polypharmacy. Current findings also highlight differences between the most commonly used atypical antipsychotics on the rate and duration of antipsychotic monotherapy, and its inverse, antipsychotic polypharmacy. Future research is needed to clarify the reasons for the observed treatment group differences, and to investigate the potential impact of antipsychotic polypharmacy on the costs of treatment and other important treatment outcomes in the long-term medication management of patients with schizophrenia.</p></div><div id="__sec17" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-19"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-20">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec17title">Competing interests</h2><p id="__p60" class="p p-first-last">The Schizophrenia Care and Assessment Program (SCAP-US) was funded by Eli Lilly and Company. The article-processing charge for this article was paid by Eli Lilly and Company. Dr. Kane serves as a consultant and/or lecturer for Eli Lilly and Company, Abbot, Bristol-Meyers Squibb, Pfizer and Janssen. Dr. Correll serves as a consultant and/or lecturer for Astra Zeneca, Bristol-Meyers Squibb, Elli Lilly and Company, and Janssen. Drs. Ascher-Svanum, Faries and Zhu are employees of Eli Lilly and Company. Drs. Ascher-Svanum, Faries and Zhu are minor stock holders in Eli Lilly and Company. Drs. Kane and Correll do not hold any stocks or shares in an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future. The authors do not hold and are not applying for any patents relating to the content of the manuscript, and have not received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript. The authors have no other financial competing interests, and have no non-financial competing interests.</p></div><div id="__sec18" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-21"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-22">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec18title">Authors' contributions</h2><p id="__p61" class="p p-first-last">DF conceived of the study, designed the analytical plan, performed the statistical analyses, interpreted the results, and drafted the manuscript. HAS participated in study design, the analytical plan, interpretation of the results, and drafted the manuscript. BZ participated in study design, the analytical plan, statistical analyses, interpretation of the results, and the drafting of the manuscript. JK participated in the design of the analytical plan, interpretation of the results, and the drafting of the manuscript. CC participated in the design of the analytical plan, interpretation of the results, and the drafting of the manuscript.</p></div><div id="__sec19" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-23"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-24">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec19title">Pre-publication history</h2><p id="__p62" class="p p-first">The pre-publication history for this paper can be accessed here:</p><p id="__p63" class="p p-last"><a href="http://www.biomedcentral.com/1471-244X/5/26/prepub" ref="reftype=extlink&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal" target="pmc_ext">http://www.biomedcentral.com/1471-244X/5/26/prepub</a></p></div><div id="__ref-listid596855" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-25"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-26">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__ref-listid596855title">References</h2><div class="ref-list-sec sec" id="reference-list"><ul class="back-ref-list" style="list-style-type:decimal;"><li id="B1"><span class="citation">American Psychiatric Association  . <span class="ref-journal">Am J Psychiatry.</span> 2. Vol. 161. American Psychiatric Association; 2004. Practice Guidelines for the Treatment of Patients with Schizophrenia; pp. 1–56.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15000267" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span> <span class="nowrap ref crossref">[<a href="http://dx.doi.org/10.1176%2Fappi.ajp.161.1.1" target="pmc_ext" ref="reftype=other&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">Cross Ref</a>]</span></span></li><li id="B2"><span class="citation">Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, Green-Paden LD, Tenhula WN, Boerescu D, Tek C, Sandson N, Steinwachs DM. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. <span><span class="ref-journal">Schizophr Bull. </span>2004;<span class="ref-vol">30</span>:193–217.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15279040" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></li><li id="B3"><span class="citation">National Institute for Clinical Excellence  . <span class="ref-journal">Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia.</span> Technology Appraisal Guidance London; 2002. </span></li><li id="B4"><span class="citation">Miller AL, Chiles JA, Chiles JK, Crismon ML, Rush AJ, Shon SP. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. <span><span class="ref-journal">J Clin Psychiatry. </span>1999;<span class="ref-vol">60</span>:649–657.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10549680" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></li><li id="B5"><span class="citation">The expert consensus guideline series  Treatment of schizophrenia. <span class="ref-journal">J Clin Psychiatry.</span> 1999. pp. 3–80.  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10380713" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></li><li id="B6"><span class="citation">Weiden PJ, Casey DE. "Polypharmacy": Combining antipsychotic medications in the treatment of schizophrenia. <span><span class="ref-journal">J Prac Psych and Behav Hlth. </span>1999;<span class="ref-vol">7</span>:229–233.</span></span></li><li id="B7"><span class="citation">Miller AL, Craig CS. Combination antipsychotics: pros, cons, and questions. <span><span class="ref-journal">Schizophr Bull. </span>2002;<span class="ref-vol">28</span>:105–109.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12047009" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></li><li id="B8"><span class="citation">Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC. Prevalence, Trends, and Factors Associated With Antipsychotic Polypharmacy Among Medicaid-Eligible Schizophrenia Patients, 1998–2000. <span><span class="ref-journal">J Clin Psychiatry. </span>2004;<span class="ref-vol">65</span>:1377–1388.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15491242" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></li><li id="B9"><span class="citation">Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N. Combination antipsychotic therapy in clinical practice. <span><span class="ref-journal">Psychiatr Serv. </span>2003;<span class="ref-vol">54</span>:55–59. doi: 10.1176/appi.ps.54.1.55.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12509667" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span> <span class="nowrap ref crossref">[<a href="http://dx.doi.org/10.1176%2Fappi.ps.54.1.55" target="pmc_ext" ref="reftype=other&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">Cross Ref</a>]</span></span></li><li id="B10"><span class="citation">Loosbrock DL, Zhao Z. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia. <span><span class="ref-journal">Journal of Mental Health Policy Economics. </span>2003;<span class="ref-vol">6</span>:67–75.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/14578539" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></li><li id="B11"><span class="citation">Schumacher JE, Makela EH, Griffin HR. Multiple antipsychotic medication prescribing patterns. <span><span class="ref-journal">Annals of Pharmacotherapy. </span>2003;<span class="ref-vol">37</span>:951–955. doi: 10.1345/aph.1C420.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12841799" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span> <span class="nowrap ref crossref">[<a href="http://dx.doi.org/10.1345%2Faph.1C420" target="pmc_ext" ref="reftype=other&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">Cross Ref</a>]</span></span></li><li id="B12"><span class="citation">McCue RE, Waheed R, Urcuyo L. Polypharmacy in patients with schizophrenia. <span><span class="ref-journal">Journal of Clinical Psychiatry. </span>2003;<span class="ref-vol">64</span>:984–989.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/14628972" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></li><li id="B13"><span class="citation">Stahl SM. Antipsychotic polypharmacy: Squandering precious resources? <span><span class="ref-journal">J Clin Psychiatry. </span>2002;<span class="ref-vol">63</span>:93–94.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11874226" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></li><li id="B14"><span class="citation">Covell NH, Jackson CT, Evans AC, Essock SM. Antipsychotic prescribing practices in Connecticut's Public Mental Health System: Rates of changing medications and prescribing styles. <span><span class="ref-journal">Schizophr Bull. </span>2002;<span class="ref-vol">28</span>:17–29.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12047017" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></li><li id="B15"><span class="citation">Weissman EM. Antipsychotic prescribing practices in the Veterans Healthcare Administartion – New York Metropolitan Region. <span><span class="ref-journal">Schizoph Bull. </span>2002;<span class="ref-vol">28</span>:31–42.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12047020" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></li><li id="B16"><span class="citation">Centorrino F, Goren JL, Hennen J, Salavtore P, Kelleher JP, Baldessarini RJ. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks versus benefits. <span><span class="ref-journal">Am J Psychiatry. </span>2004;<span class="ref-vol">161</span>:700–706. doi: 10.1176/appi.ajp.161.4.700.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15056517" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span> <span class="nowrap ref crossref">[<a href="http://dx.doi.org/10.1176%2Fappi.ajp.161.4.700" target="pmc_ext" ref="reftype=other&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">Cross Ref</a>]</span></span></li><li id="B17"><span class="citation">Clark RE, Bartels SJ, Mellman TA, Peacock WJ. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. <span><span class="ref-journal">Schizophr Bull. </span>2002;<span class="ref-vol">28</span>:75–84.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12047024" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></li><li id="B18"><span class="citation">Jerrell JM. Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications. <span><span class="ref-journal">Schizophr Bull. </span>2002;<span class="ref-vol">28</span>:589–605.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12795493" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></li><li id="B19"><span class="citation">Procyshyn RM, Kennedy NB, Tse G, Thompson B. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. <span><span class="ref-journal">Can J Psychiatry. </span>2001;<span class="ref-vol">46</span>:334–339.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11387789" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></li><li id="B20"><span class="citation">Yuzda MSK. Combination antipsychotics: what is the evidence? <span><span class="ref-journal">J Inform Pharamcother. </span>2000;<span class="ref-vol">2</span>:300–305.</span></span></li><li id="B21"><span class="citation">Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. <span><span class="ref-journal">Acta Psychiatr Scand. </span>2002;<span class="ref-vol">106</span>:323–330. doi: 10.1034/j.1600-0447.2002.01331.x.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12366465" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span> <span class="nowrap ref crossref">[<a href="http://dx.doi.org/10.1034%2Fj.1600-0447.2002.01331.x" target="pmc_ext" ref="reftype=other&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">Cross Ref</a>]</span></span></li><li id="B22"><span class="citation">Meltzer HY, Kostakoglu A. Combining antipsychotics: is there evidence for efficacy? <span><span class="ref-journal">Psychiatric Times. </span>2000;<span class="ref-vol">17</span>:25–32.</span></span></li><li id="B23"><span class="citation">Chiles JA, Miller AL, Crismon LM, Rush AJ, Krasnoff AS, Shon SS. The Texas medication algorithm project: development and implementation of the schizophrenia algorithm. <span><span class="ref-journal">Psychiatr Serv. </span>1999;<span class="ref-vol">50</span>:69–74.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9890582" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></li><li id="B24"><span class="citation">Koshino Y. Algorithm for treatment-refractory schizophrenia. <span><span class="ref-journal">Psychiatry Clin Neurosci. </span>1999;<span class="ref-vol">53</span>:S9–S13.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10560891" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></li><li id="B25"><span class="citation">Jaffe AB, Levine J. Antipsychotic medication coprescribing in a large state hospital system. <span><span class="ref-journal">Pharmacoepidemiol Drug Saf. </span>2003;<span class="ref-vol">12</span>:41–48. doi: 10.1002/pds.783.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12616846" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span> <span class="nowrap ref crossref">[<a href="http://dx.doi.org/10.1002%2Fpds.783" target="pmc_ext" ref="reftype=other&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">Cross Ref</a>]</span></span></li><li id="B26"><span class="citation">Advokat C, Dixon D, Schnedier J, Comaty JE. Comparison of risperidone and olanzapine as used under "real world" conditions in a state psychiatric hospital. <span><span class="ref-journal">Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry. </span>2004;<span class="ref-vol">28</span>:484–495.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15093956" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></li><li id="B27"><span class="citation">Correll CU, Kane JM, O'Shea D, Razi K, Malhotra AK. Antipsychotic polypharmacy inn the treatment of schizophrenia. <span><span class="ref-journal">Schizophr Res. </span>2003:37. doi: 10.1016/S0920-9964(03)80107-X.</span> <span class="nowrap ref crossref">[<a href="http://dx.doi.org/10.1016%2FS0920-9964(03)80107-X" target="pmc_ext" ref="reftype=other&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">Cross Ref</a>]</span></span></li><li id="B28"><span class="citation">Gibson PJ, Damler R, Jackson EA, Wilder T, Ramsey J. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a Medicaid population. <span><span class="ref-journal">Value in Health. </span>2004;<span class="ref-vol">7</span>:22–35. doi: 10.1111/j.1524-4733.2004.71272.x.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/14720128" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span> <span class="nowrap ref crossref">[<a href="http://dx.doi.org/10.1111%2Fj.1524-4733.2004.71272.x" target="pmc_ext" ref="reftype=other&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">Cross Ref</a>]</span></span></li><li id="B29"><span class="citation">Zhao Z, Tunis SL, Lage M. Medication treatment patterns following initiation on olanzapine versus risperidone. <span><span class="ref-journal">Clin Drug Invest. </span>2002;<span class="ref-vol">22</span>:741–749.</span></span></li><li id="B30"><span class="citation">Wang PF, Zhao Z. Comparison of olanzapine versus quetiapine in the treatment of hospitalized patients with schizophrenia. <span><span class="ref-journal">Value in Health. </span>2003;<span class="ref-vol">6</span>:355.</span></span></li><li id="B31"><span class="citation">Ascher-Svanum H, Zhu B, Faries D, Ernst FR. A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia. <span><span class="ref-journal">Ann Gen Hosp Psychiatry. </span>2004;<span class="ref-vol">3</span></span> Epub June 02, 2004. <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC428579/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15175112" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></li><li id="B32"><span class="citation">Swanson JW, Swartz MS, Elbogen EB. Effectiveness of Atypical Antipsychotic Medications in Reducing Violent Behavior Among Persons with Schizophrenia in Community-Based Treatment. <span><span class="ref-journal">Schizophr Bull. </span>2004;<span class="ref-vol">30</span>:3–20.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15176758" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></li><li id="B33"><span class="citation">Liang KY, Zeger SL. Longitudinal Data Analysis Using Generalized Linear Models. <span><span class="ref-journal">Biometrika. </span>1986;<span class="ref-vol">73</span>:13–22.</span></span></li><li id="B34"><span class="citation">Chernick MR.  <span class="ref-journal">Bootstrap Methods: A Practicioner's Guide.</span> John Wiley &amp; Sons, Inc. New York, NY; 1999. </span></li><li id="B35"><span class="citation">Davis J, Chen N. Dose response and dose equivalence of antipsychotics. <span><span class="ref-journal">J Clin Psychopharmacol. </span>2004;<span class="ref-vol">24</span>:192–208. doi: 10.1097/01.jcp.0000117422.05703.ae.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15206667" target="pmc_ext" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span> <span class="nowrap ref crossref">[<a href="http://dx.doi.org/10.1097%2F01.jcp.0000117422.05703.ae" target="pmc_ext" ref="reftype=other&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">Cross Ref</a>]</span></span></li><li id="B36"><span class="citation">Rupnow M, Stahl S, Greenspan A, Kosik-Gonzalez C, Gharabawi G. Use and cost of polypharmacy in schizophrenia: Data from a randomized double-blind study of risperidone and quetiapine. <span><span class="ref-journal">Schizophr Bull. </span>2005;<span class="ref-vol">31</span>:550.</span></span></li></ul></div></div><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu"><ul id="ui-ncbiinpagenav-2"><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#__abstractid871854title">Abstract</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#__sec5title">Background</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#__sec6title">Methods</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#__sec10title">Results</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#__sec15title">Discussion</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#__sec16title">Conclusion</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#__sec17title">Competing interests</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#__sec18title">Authors' contributions</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#__sec19title">Pre-publication history</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#__ref-listid596855title">References</a></li></ul></div></div><!--post-content--><hr class="whole_rhythm no_bottom_margin"><div class="courtesy-note no_margin small">Articles from <span class="acknowledgment-journal-title">BMC Psychiatry</span> are provided here courtesy of <strong>BioMed Central</strong></div></div>
            
            
        
            
        </div>
        <!-- Book content -->
    </div>
    
    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            
        </div>
        
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="try-button"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/?report=reader"><img src="./PMC1156914_files/3838809" alt="PubReader format: click here to try"></a></div><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/epub/">ePub (beta)</a></li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/pdf/1471-244X-5-26.pdf">PDF (526K)</a></li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#" data-citationid="PMC1156914" class="citationexporter ctxp" role="button" aria-expanded="false" aria-haspopup="true">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1156914%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC1156914_files/4047626" alt="Share on Facebook">
                             Facebook
                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1156914%2F&amp;text=Antipsychotic%20monotherapy%20and%20polypharmacy%20in%20the%20naturalistic%20treatment%20of%20schizophrenia%20with%20atypical%20antipsychotics" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC1156914_files/4047627" alt="Share on Twitter">
                             Twitter
                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1156914%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC1156914_files/4047628" alt="Share on Google Plus">
                             Google+
                        </a></li></ul></div>
        
        <div id="ajax-portlets" data-pmid="15921508" data-aiid="1156914" data-aid="1156914" data-iid="18178" data-domainid="62" data-domain="bmcpsyc" data-accid="PMC1156914" data-md5="7a0ec3cbf1fd7fe427a6cf7562f0b2a4">
<div class="portlet pubmed_favoritesad">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Save items</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="pmfavad" toggles="ui-portlet_content-29" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-29" aria-hidden="false"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<input type="hidden" name="absid" id="absid" value="1156914"><div id="pubmed_favoritesad" class="empty" data-db="pmc">
<span role="menubar"><div class="ui-ncbisetswitch ltd-hover" role="menuitem" aria-expanded="false" aria-haspopup="true"><a href="http://www.ncbi.nlm.nih.gov/myncbi/collections/" class="jig-ncbisetswitch blind collink ltd-hover ui-ncbisetswitch-hasStar" id="favList" data-jigconfig="destSelector:&#39;#favUL&#39;,starExists:true,createCollectionUrl:&#39;#&#39;,manageCollectionsUrl:&#39;/myncbi/collections/&#39;"><span class="star"></span>Add to Favorites</a><a class="ui-ncbisetswitch-button ltd-hover" title="View more options" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#"><span class="ui-icon ui-icon-triangle-1-s ui-ncbisetswitch-down">View more options</span></a></div></span><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu ui-ncbisetswitch-popper"><ul id="favUL" class="ui-ncbisetswitch-options"></ul><ul class="ui-ncbisetswitch-actions"><li class="ui-ncbisetswitch-actions-create" style="display: block;"><a class="ui-ncbisetswitch-create-collection" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#">Create collection...</a></li><li class="ui-ncbisetswitch-actions-manage" style="display: block;"><a class="ui-ncbisetswitch-manage-collections" href="http://www.ncbi.nlm.nih.gov/myncbi/collections/">Manage collections...</a></li></ul></div>
</div>
<div class="colloading">loading</div>
<span id="submenu_AddToCollections"><form method="post"><input type="submit" class="button_apply" name="addtocollection" value="1"></form></span>
</div></div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" toggles="ui-portlet_content-31" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-31" aria-hidden="false">
<ul>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/18394168" ref="reftype=relart&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Cost of antipsychotic polypharmacy in the treatment of schizophrenia.</a><span class="source">[BMC Psychiatry. 2008]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-33" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Zhu B, Ascher-Svanum H, Faries DE, Correll CU, Kane JM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">BMC Psychiatry. 2008 Apr 4; 8:19. Epub 2008 Apr 4.</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/22759944" ref="reftype=relart&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European Schizophrenia Outpatient Health Outcomes Study.</a><span class="source">[J Nerv Ment Dis. 2012]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-35" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Novick D, Ascher-Svanum H, Brugnoli R, Bertsch J, Hong J, Haro JM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Nerv Ment Dis. 2012 Jul; 200(7):637-43. </em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/16504026" ref="reftype=relart&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.</a><span class="source">[BMC Psychiatry. 2006]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-37" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">BMC Psychiatry. 2006 Feb 21; 6:8. Epub 2006 Feb 21.</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/15959450" ref="reftype=relart&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="true" aria-haspopup="true">[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].</a><span class="source">[Encephale. 2005]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-39" aria-live="assertive" aria-hidden="false" style="top: 566.953px; left: 511.453px; display: block;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Encephale. 2005 Mar-Apr; 31(2):235-46. </em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/23055416" ref="reftype=relart&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.</a><span class="source">[Hum Psychopharmacol. 2011]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-41" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Krzystanek M, Krupka-Matuszczyk I. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Hum Psychopharmacol. 2011 Jan; 26(1):81-5. Epub 2011 Feb 9.</em>
</div>
</li>
</ul>
<a class="seemore" href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=15921508&amp;log%24=relatedreviews&amp;logdbfrom=pmc" ref="reftype=relart&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Reviews&amp;rendering-type=normal">See reviews...</a><a class="seemore" href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=15921508&amp;log%24=relatedarticles&amp;logdbfrom=pmc" ref="reftype=relart&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Related%20Records&amp;rendering-type=normal">See all...</a>
</div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Cited by other articles in PMC</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PMCVCitedByPmcArticlesP" toggles="ui-portlet_content-43" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-43" aria-hidden="false">
<ul>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4745389/" ref="reftype=relart&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Prevalence of Antipsychotic Polypharmacy and Associated Factors among Outpatients with Schizophrenia Attending Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia</a><span class="source">[Psychiatry Journal. 2016]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-45" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Tesfaye S, Debencho N, Kisi T, Tareke M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Psychiatry Journal. 2016 Jan 24; 20166191074</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728749/" ref="reftype=relart&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports</a><span class="source">[Journal of Pharmaceutical Heal...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-47" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kato Y, Umetsu R, Abe J, Ueda N, Nakayama Y, Kinosada Y, Nakamura M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Journal of Pharmaceutical Health Care and Sciences. 2015 Apr 16; 115</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4486331/" ref="reftype=relart&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Validation of a claims-based antipsychotic polypharmacy measure</a><span class="source">[Pharmacoepidemiology and drug ...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-49" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Leckman-Westin E, Kealey E, Gupta N, Chen Q, Gerhard T, Crystal S, Olfson M, Finnerty M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Pharmacoepidemiology and drug safety. 2014 Mar 24; 23(6)628-635</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4432466/" ref="reftype=relart&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Polypharmacy with antipsychotic drugs in patients with schizophrenia: trends in multiple health care systems</a><span class="source">[American journal of health-sys...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-51" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sun F, Stock EM, Copeland LA, Zeber JE, Ahmedani BK, Morissette SB. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2014 May 1; 71(9)728-738</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264319/" ref="reftype=relart&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy</a><span class="source">[BMC Psychiatry. 2014]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-53" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Fisher MD, Reilly K, Isenberg K, Villa KF. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">BMC Psychiatry. 2014 Nov 30; 14341</em>
</div>
</li>
</ul>
<a class="seemore" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/citedby/" ref="reftype=relart&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|CitedBy&amp;rendering-type=normal">See all...</a>
</div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Links</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PMCVCitedByPmcArticlesP" toggles="ui-portlet_content-55" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-55" aria-hidden="false"><ul>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=pccompound&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_pccompound&amp;IdsFromResult=1156914" ref="reftype=Compound&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|PubChem%20Compound&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Compound</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-57" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">Compound<div class="brieflinkpopdesc">PubChem Compound links</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=medgen&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_medgen&amp;IdsFromResult=1156914" ref="reftype=MedGen&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|Unknown%20Link%20Name&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">MedGen</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-59" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">MedGen<div class="brieflinkpopdesc">Related information in MedGen</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/15921508/" ref="reftype=PubMed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|PubMed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">PubMed</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-61" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">PubMed<div class="brieflinkpopdesc">PubMed citations for these articles</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=pcsubstance&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_pcsubstance&amp;IdsFromResult=1156914" ref="reftype=Substance&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|PubChem%20Substance&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Substance</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-63" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">Substance<div class="brieflinkpopdesc">PubChem Substance links</div>
</div>
</li>
</ul></div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Recent Activity</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" toggles="ui-portlet_content-65" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-65" aria-hidden="false"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class="">
<div class="action">
<a href="javascript:historyDisplayState(&#39;ClearHT&#39;)">Clear</a><a href="javascript:historyDisplayState(&#39;HTOff&#39;)" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState(&#39;HTOn&#39;)" class="HTOff">Turn On</a>
</div>
<ul id="activity">
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c265404fcfad5917677c1">Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schi...</a><div class="ralinkpop offscreen_noflow">Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics<div class="brieflinkpopdesc">BMC Psychiatry. 2005; 5()26</div>
</div>
<div class="tertiary"></div>
</li>
<li class="ra_qry two_line">
<a class="htb" ref="log$=activity&amp;linkpos=2" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c264804fcfad591767587">PMC1156914 <span class="number">(1)</span></a><div class="tertiary">PMC</div>
</li>
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=3" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c261af2911de5257d465f">Pharmacokinetic Interactions between Nelfinavir and 3-Hydroxy-3-Methylglutaryl C...</a><div class="ralinkpop offscreen_noflow">Pharmacokinetic Interactions between Nelfinavir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Simvastatin<div class="brieflinkpopdesc">Antimicrobial Agents and Chemotherapy. 2001 Dec; 45(12)3445</div>
</div>
<div class="tertiary"></div>
</li>
<li class="ra_qry two_line">
<a class="htb" ref="log$=activity&amp;linkpos=4" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c2618f0c03b7981753c95">PMC90851 <span class="number">(1)</span></a><div class="tertiary">PMC</div>
</li>
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=5" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c25c97fd84438f0e9aaf9">Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegati...</a><div class="ralinkpop offscreen_noflow">Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108<div class="brieflinkpopdesc">NIHPA Author Manuscripts. 2006 Mar 21; 20(5)725</div>
</div>
<div class="tertiary"></div>
</li>
</ul>
<p class="HTOn">Your browsing activity is empty.</p>
<p class="HTOff">Activity recording is turned off.</p>
<p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState(&#39;HTOn&#39;)">Turn recording back on</a></p>
<a class="seemore" href="http://www.ncbi.nlm.nih.gov/sites/myncbi/recentactivity">See more...</a>
</div></div></div>
</div>
<div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p6" name="crb--__p6" rid="__p6" style="position: absolute; visibility: visible; width: 370px; top: 1251px; display: none;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-67"><ul>
<li class="two_line" reference_id="B1">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15000267/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Practice guideline for the treatment of patients with schizophrenia, second edition.</a><span class="one_line_source">[Am J Psychiatry.  2004]</span><div class="alt-note">
<div class="authors">Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J, American Psychiatric Association, Steering Committee on Practice Guidelines</div>
<div class="citation">Am J Psychiatry. 2004 Feb; 161(2 Suppl):1-56.</div>
</div>
</li>
<li class="two_line" reference_id="B5">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/10380713/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Treatment of schizophrenia 1999. The expert consensus guideline series.</a><span class="one_line_source">[J Clin Psychiatry.  1999]</span><div class="alt-note">
<div class="authors"></div>
<div class="citation">J Clin Psychiatry. 1999; 60 Suppl 11():3-80.</div>
</div>
</li>
<li class="two_line" reference_id="B4">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/10549680/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms.</a><span class="one_line_source">[J Clin Psychiatry.  1999]</span><div class="alt-note">
<div class="authors">Miller AL, Chiles JA, Chiles JK, Crismon ML, Rush AJ, Shon SP</div>
<div class="citation">J Clin Psychiatry. 1999 Oct; 60(10):649-57.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p7" name="crb--__p7" rid="__p7" style="position: absolute; visibility: visible; width: 370px; top: 1409px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-68"><ul><li class="two_line" reference_id="B7">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12047009/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Combination antipsychotics: pros, cons, and questions.</a><span class="one_line_source">[Schizophr Bull.  2002]</span><div class="alt-note">
<div class="authors">Miller AL, Craig CS</div>
<div class="citation">Schizophr Bull. 2002; 28(1):105-9.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p8" name="crb--__p8" rid="__p8" style="position: absolute; visibility: visible; width: 370px; top: 1525px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-69"><ul>
<li class="two_line" reference_id="B7">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12047009/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Combination antipsychotics: pros, cons, and questions.</a><span class="one_line_source">[Schizophr Bull.  2002]</span><div class="alt-note">
<div class="authors">Miller AL, Craig CS</div>
<div class="citation">Schizophr Bull. 2002; 28(1):105-9.</div>
</div>
</li>
<li class="two_line" reference_id="B15">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12047020/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Antipsychotic prescribing practices in the Veterans Healthcare Administration--New York metropolitan region.</a><span class="one_line_source">[Schizophr Bull.  2002]</span><div class="alt-note">
<div class="authors">Weissman EM</div>
<div class="citation">Schizophr Bull. 2002; 28(1):31-42.</div>
</div>
</li>
<li class="two_line" reference_id="B8">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15491242/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.</a><span class="one_line_source">[J Clin Psychiatry.  2004]</span><div class="alt-note">
<div class="authors">Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC</div>
<div class="citation">J Clin Psychiatry. 2004 Oct; 65(10):1377-88.</div>
</div>
</li>
<li class="two_line" reference_id="B9" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12509667/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Combination antipsychotic therapy in clinical practice.</a><span class="one_line_source">[Psychiatr Serv.  2003]</span><div class="alt-note">
<div class="authors">Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N</div>
<div class="citation">Psychiatr Serv. 2003 Jan; 54(1):55-9.</div>
</div>
</li>
<li class="two_line" reference_id="B14" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12047017/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles.</a><span class="one_line_source">[Schizophr Bull.  2002]</span><div class="alt-note">
<div class="authors">Covell NH, Jackson CT, Evans AC, Essock SM</div>
<div class="citation">Schizophr Bull. 2002; 28(1):17-29.</div>
</div>
</li>
<li class="two_line" reference_id="B16" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15056517/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits.</a><span class="one_line_source">[Am J Psychiatry.  2004]</span><div class="alt-note">
<div class="authors">Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ</div>
<div class="citation">Am J Psychiatry. 2004 Apr; 161(4):700-6.</div>
</div>
</li>
<li class="two_line" reference_id="B19" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/11387789/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution.</a><span class="one_line_source">[Can J Psychiatry.  2001]</span><div class="alt-note">
<div class="authors">Procyshyn RM, Kennedy NB, Tse G, Thompson B</div>
<div class="citation">Can J Psychiatry. 2001 May; 46(4):334-9.</div>
</div>
</li>
</ul><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/" class="seemore">See more ...</a></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p9" name="crb--__p9" rid="__p9" style="position: absolute; visibility: visible; width: 370px; top: 1683px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-70"><ul>
<li class="two_line" reference_id="B7" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12047009/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Combination antipsychotics: pros, cons, and questions.</a><span class="one_line_source">[Schizophr Bull.  2002]</span><div class="alt-note">
<div class="authors">Miller AL, Craig CS</div>
<div class="citation">Schizophr Bull. 2002; 28(1):105-9.</div>
</div>
</li>
<li class="two_line" reference_id="B8" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15491242/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.</a><span class="one_line_source">[J Clin Psychiatry.  2004]</span><div class="alt-note">
<div class="authors">Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC</div>
<div class="citation">J Clin Psychiatry. 2004 Oct; 65(10):1377-88.</div>
</div>
</li>
<li class="two_line" reference_id="B21" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12366465/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations.</a><span class="one_line_source">[Acta Psychiatr Scand.  2002]</span><div class="alt-note">
<div class="authors">Freudenreich O, Goff DC</div>
<div class="citation">Acta Psychiatr Scand. 2002 Nov; 106(5):323-30.</div>
</div>
</li>
<li class="two_line" reference_id="B9" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12509667/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Combination antipsychotic therapy in clinical practice.</a><span class="one_line_source">[Psychiatr Serv.  2003]</span><div class="alt-note">
<div class="authors">Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N</div>
<div class="citation">Psychiatr Serv. 2003 Jan; 54(1):55-9.</div>
</div>
</li>
<li class="two_line" reference_id="B11" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12841799/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Multiple antipsychotic medication prescribing patterns.</a><span class="one_line_source">[Ann Pharmacother.  2003]</span><div class="alt-note">
<div class="authors">Schumacher JE, Makela EH, Griffin HR</div>
<div class="citation">Ann Pharmacother. 2003 Jul-Aug; 37(7-8):951-5.</div>
</div>
</li>
<li class="two_line" reference_id="B13" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/11874226/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Antipsychotic polypharmacy: squandering precious resources?</a><span class="one_line_source">[J Clin Psychiatry.  2002]</span><div class="alt-note">
<div class="authors">Stahl SM</div>
<div class="citation">J Clin Psychiatry. 2002 Feb; 63(2):93-4.</div>
</div>
</li>
<li class="two_line" reference_id="B24" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/10560891/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Algorithm for treatment-refractory schizophrenia.</a><span class="one_line_source">[Psychiatry Clin Neurosci.  1999]</span><div class="alt-note">
<div class="authors">Koshino Y</div>
<div class="citation">Psychiatry Clin Neurosci. 1999 Oct; 53 Suppl():S9-13.</div>
</div>
</li>
</ul><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/" class="seemore">See links ...</a></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p10" name="crb--__p10" rid="__p10" style="position: absolute; visibility: visible; width: 370px; top: 1757px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-71"><ul>
<li class="two_line" reference_id="B7">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12047009/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Combination antipsychotics: pros, cons, and questions.</a><span class="one_line_source">[Schizophr Bull.  2002]</span><div class="alt-note">
<div class="authors">Miller AL, Craig CS</div>
<div class="citation">Schizophr Bull. 2002; 28(1):105-9.</div>
</div>
</li>
<li class="two_line" reference_id="B10">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/14578539/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.</a><span class="one_line_source">[J Ment Health Policy Econ.  2003]</span><div class="alt-note">
<div class="authors">Loosbrock DL, Zhao Z, Johnstone BM, Morris LS</div>
<div class="citation">J Ment Health Policy Econ. 2003 Jun; 6(2):67-75.</div>
</div>
</li>
<li class="two_line" reference_id="B25">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12616846/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Antipsychotic medication coprescribing in a large state hospital system.</a><span class="one_line_source">[Pharmacoepidemiol Drug Saf.  2003]</span><div class="alt-note">
<div class="authors">Jaffe AB, Levine J</div>
<div class="citation">Pharmacoepidemiol Drug Saf. 2003 Jan-Feb; 12(1):41-8.</div>
</div>
</li>
<li class="two_line" reference_id="B16" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15056517/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits.</a><span class="one_line_source">[Am J Psychiatry.  2004]</span><div class="alt-note">
<div class="authors">Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ</div>
<div class="citation">Am J Psychiatry. 2004 Apr; 161(4):700-6.</div>
</div>
</li>
</ul><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/" class="seemore">See more ...</a></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p11" name="crb--__p11" rid="__p11" style="position: absolute; visibility: visible; width: 370px; top: 1915px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-72"><ul>
<li class="two_line" reference_id="B7">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12047009/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Combination antipsychotics: pros, cons, and questions.</a><span class="one_line_source">[Schizophr Bull.  2002]</span><div class="alt-note">
<div class="authors">Miller AL, Craig CS</div>
<div class="citation">Schizophr Bull. 2002; 28(1):105-9.</div>
</div>
</li>
<li class="two_line" reference_id="B11" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12841799/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Multiple antipsychotic medication prescribing patterns.</a><span class="one_line_source">[Ann Pharmacother.  2003]</span><div class="alt-note">
<div class="authors">Schumacher JE, Makela EH, Griffin HR</div>
<div class="citation">Ann Pharmacother. 2003 Jul-Aug; 37(7-8):951-5.</div>
</div>
</li>
<li class="two_line" reference_id="B9" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12509667/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Combination antipsychotic therapy in clinical practice.</a><span class="one_line_source">[Psychiatr Serv.  2003]</span><div class="alt-note">
<div class="authors">Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N</div>
<div class="citation">Psychiatr Serv. 2003 Jan; 54(1):55-9.</div>
</div>
</li>
</ul><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/" class="seemore">See more ...</a></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p12" name="crb--__p12" rid="__p12" style="position: absolute; visibility: visible; width: 370px; top: 2010px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-73"><ul>
<li class="two_line" reference_id="B8">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15491242/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.</a><span class="one_line_source">[J Clin Psychiatry.  2004]</span><div class="alt-note">
<div class="authors">Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC</div>
<div class="citation">J Clin Psychiatry. 2004 Oct; 65(10):1377-88.</div>
</div>
</li>
<li class="two_line" reference_id="B26">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15093956/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Comparison of risperidone and olanzapine as used under "real-world" conditions in a state psychiatric hospital.</a><span class="one_line_source">[Prog Neuropsychopharmacol Biol Psychiatry.  2004]</span><div class="alt-note">
<div class="authors">Advokat C, Dixon D, Schneider J, Comaty JE Jr</div>
<div class="citation">Prog Neuropsychopharmacol Biol Psychiatry. 2004 May; 28(3):487-95.</div>
</div>
</li>
<li class="two_line" reference_id="B18">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12795493/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications.</a><span class="one_line_source">[Schizophr Bull.  2002]</span><div class="alt-note">
<div class="authors">Jerrell JM</div>
<div class="citation">Schizophr Bull. 2002; 28(4):589-605.</div>
</div>
</li>
<li class="two_line" reference_id="B19">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/11387789/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution.</a><span class="one_line_source">[Can J Psychiatry.  2001]</span><div class="alt-note">
<div class="authors">Procyshyn RM, Kennedy NB, Tse G, Thompson B</div>
<div class="citation">Can J Psychiatry. 2001 May; 46(4):334-9.</div>
</div>
</li>
<li class="two_line" reference_id="B28" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/14720128/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.</a><span class="one_line_source">[Value Health.  2004]</span><div class="alt-note">
<div class="authors">Gibson PJ, Damler R, Jackson EA, Wilder T, Ramsey JL</div>
<div class="citation">Value Health. 2004 Jan-Feb; 7(1):22-35.</div>
</div>
</li>
<li class="two_line" reference_id="B25" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12616846/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Antipsychotic medication coprescribing in a large state hospital system.</a><span class="one_line_source">[Pharmacoepidemiol Drug Saf.  2003]</span><div class="alt-note">
<div class="authors">Jaffe AB, Levine J</div>
<div class="citation">Pharmacoepidemiol Drug Saf. 2003 Jan-Feb; 12(1):41-8.</div>
</div>
</li>
</ul><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/" class="seemore">See more ...</a></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p17" name="crb--__p17" rid="__p17" style="position: absolute; visibility: visible; width: 370px; top: 2832px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-74"><ul>
<li class="two_line" reference_id="B31">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15175112/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia.</a><span class="one_line_source">[Ann Gen Hosp Psychiatry.  2004]</span><div class="alt-note">
<div class="authors">Ascher-Svanum H, Zhu B, Faries D, Ernst FR</div>
<div class="citation">Ann Gen Hosp Psychiatry. 2004 Jun 2; 3(1):11.</div>
</div>
</li>
<li class="two_line" reference_id="B32">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15176758/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment.</a><span class="one_line_source">[Schizophr Bull.  2004]</span><div class="alt-note">
<div class="authors">Swanson JW, Swartz MS, Elbogen EB</div>
<div class="citation">Schizophr Bull. 2004; 30(1):3-20.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p20" name="crb--__p20" rid="__p20" style="position: absolute; visibility: visible; width: 370px; top: 3362px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-75"><ul><li class="two_line" reference_id="B5">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/10380713/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Treatment of schizophrenia 1999. The expert consensus guideline series.</a><span class="one_line_source">[J Clin Psychiatry.  1999]</span><div class="alt-note">
<div class="authors"></div>
<div class="citation">J Clin Psychiatry. 1999; 60 Suppl 11():3-80.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p52" name="crb--__p52" rid="__p52" style="position: absolute; visibility: visible; width: 370px; top: 7138px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-76"><ul>
<li class="two_line" reference_id="B15">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12047020/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Antipsychotic prescribing practices in the Veterans Healthcare Administration--New York metropolitan region.</a><span class="one_line_source">[Schizophr Bull.  2002]</span><div class="alt-note">
<div class="authors">Weissman EM</div>
<div class="citation">Schizophr Bull. 2002; 28(1):31-42.</div>
</div>
</li>
<li class="two_line" reference_id="B16">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15056517/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits.</a><span class="one_line_source">[Am J Psychiatry.  2004]</span><div class="alt-note">
<div class="authors">Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ</div>
<div class="citation">Am J Psychiatry. 2004 Apr; 161(4):700-6.</div>
</div>
</li>
<li class="two_line" reference_id="B19">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/11387789/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution.</a><span class="one_line_source">[Can J Psychiatry.  2001]</span><div class="alt-note">
<div class="authors">Procyshyn RM, Kennedy NB, Tse G, Thompson B</div>
<div class="citation">Can J Psychiatry. 2001 May; 46(4):334-9.</div>
</div>
</li>
<li class="two_line" reference_id="B25">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12616846/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Antipsychotic medication coprescribing in a large state hospital system.</a><span class="one_line_source">[Pharmacoepidemiol Drug Saf.  2003]</span><div class="alt-note">
<div class="authors">Jaffe AB, Levine J</div>
<div class="citation">Pharmacoepidemiol Drug Saf. 2003 Jan-Feb; 12(1):41-8.</div>
</div>
</li>
<li class="two_line" reference_id="B26">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15093956/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Comparison of risperidone and olanzapine as used under "real-world" conditions in a state psychiatric hospital.</a><span class="one_line_source">[Prog Neuropsychopharmacol Biol Psychiatry.  2004]</span><div class="alt-note">
<div class="authors">Advokat C, Dixon D, Schneider J, Comaty JE Jr</div>
<div class="citation">Prog Neuropsychopharmacol Biol Psychiatry. 2004 May; 28(3):487-95.</div>
</div>
</li>
<li class="two_line" reference_id="B10">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/14578539/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.</a><span class="one_line_source">[J Ment Health Policy Econ.  2003]</span><div class="alt-note">
<div class="authors">Loosbrock DL, Zhao Z, Johnstone BM, Morris LS</div>
<div class="citation">J Ment Health Policy Econ. 2003 Jun; 6(2):67-75.</div>
</div>
</li>
<li class="two_line" reference_id="B14">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12047017/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles.</a><span class="one_line_source">[Schizophr Bull.  2002]</span><div class="alt-note">
<div class="authors">Covell NH, Jackson CT, Evans AC, Essock SM</div>
<div class="citation">Schizophr Bull. 2002; 28(1):17-29.</div>
</div>
</li>
<li class="two_line" reference_id="B8">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15491242/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.</a><span class="one_line_source">[J Clin Psychiatry.  2004]</span><div class="alt-note">
<div class="authors">Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC</div>
<div class="citation">J Clin Psychiatry. 2004 Oct; 65(10):1377-88.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p53" name="crb--__p53" rid="__p53" style="position: absolute; visibility: visible; width: 370px; top: 7548px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-77"><ul>
<li class="two_line" reference_id="B18">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12795493/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications.</a><span class="one_line_source">[Schizophr Bull.  2002]</span><div class="alt-note">
<div class="authors">Jerrell JM</div>
<div class="citation">Schizophr Bull. 2002; 28(4):589-605.</div>
</div>
</li>
<li class="two_line" reference_id="B19">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/11387789/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution.</a><span class="one_line_source">[Can J Psychiatry.  2001]</span><div class="alt-note">
<div class="authors">Procyshyn RM, Kennedy NB, Tse G, Thompson B</div>
<div class="citation">Can J Psychiatry. 2001 May; 46(4):334-9.</div>
</div>
</li>
<li class="two_line" reference_id="B28">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/14720128/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.</a><span class="one_line_source">[Value Health.  2004]</span><div class="alt-note">
<div class="authors">Gibson PJ, Damler R, Jackson EA, Wilder T, Ramsey JL</div>
<div class="citation">Value Health. 2004 Jan-Feb; 7(1):22-35.</div>
</div>
</li>
<li class="two_line" reference_id="B25">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12616846/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Antipsychotic medication coprescribing in a large state hospital system.</a><span class="one_line_source">[Pharmacoepidemiol Drug Saf.  2003]</span><div class="alt-note">
<div class="authors">Jaffe AB, Levine J</div>
<div class="citation">Pharmacoepidemiol Drug Saf. 2003 Jan-Feb; 12(1):41-8.</div>
</div>
</li>
<li class="two_line" reference_id="B8">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15491242/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.</a><span class="one_line_source">[J Clin Psychiatry.  2004]</span><div class="alt-note">
<div class="authors">Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC</div>
<div class="citation">J Clin Psychiatry. 2004 Oct; 65(10):1377-88.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p54" name="crb--__p54" rid="__p54" style="position: absolute; visibility: visible; width: 370px; top: 7790px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-78"><ul><li class="two_line" reference_id="B14">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12047017/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles.</a><span class="one_line_source">[Schizophr Bull.  2002]</span><div class="alt-note">
<div class="authors">Covell NH, Jackson CT, Evans AC, Essock SM</div>
<div class="citation">Schizophr Bull. 2002; 28(1):17-29.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p56" name="crb--__p56" rid="__p56" style="position: absolute; visibility: visible; width: 370px; top: 8274px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-79"><ul><li class="two_line" reference_id="B35">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15206667/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Dose response and dose equivalence of antipsychotics.</a><span class="one_line_source">[J Clin Psychopharmacol.  2004]</span><div class="alt-note">
<div class="authors">Davis JM, Chen N</div>
<div class="citation">J Clin Psychopharmacol. 2004 Apr; 24(2):192-208.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p57" name="crb--__p57" rid="__p57" style="position: absolute; visibility: visible; width: 370px; top: 8516px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-80"><ul>
<li class="two_line" reference_id="B18">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/12795493/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications.</a><span class="one_line_source">[Schizophr Bull.  2002]</span><div class="alt-note">
<div class="authors">Jerrell JM</div>
<div class="citation">Schizophr Bull. 2002; 28(4):589-605.</div>
</div>
</li>
<li class="two_line" reference_id="B19">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/11387789/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution.</a><span class="one_line_source">[Can J Psychiatry.  2001]</span><div class="alt-note">
<div class="authors">Procyshyn RM, Kennedy NB, Tse G, Thompson B</div>
<div class="citation">Can J Psychiatry. 2001 May; 46(4):334-9.</div>
</div>
</li>
<li class="two_line" reference_id="B28">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/14720128/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.</a><span class="one_line_source">[Value Health.  2004]</span><div class="alt-note">
<div class="authors">Gibson PJ, Damler R, Jackson EA, Wilder T, Ramsey JL</div>
<div class="citation">Value Health. 2004 Jan-Feb; 7(1):22-35.</div>
</div>
</li>
<li class="two_line" reference_id="B35">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15206667/" ref="reftype=pubmed&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Dose response and dose equivalence of antipsychotics.</a><span class="one_line_source">[J Clin Psychopharmacol.  2004]</span><div class="alt-note">
<div class="authors">Davis JM, Chen N</div>
<div class="citation">J Clin Psychopharmacol. 2004 Apr; 24(2):192-208.</div>
</div>
</li>
</ul></div>
</div>
</div>   
    </div>
                
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script src="./PMC1156914_files/jquery.scrollTo-1.4.2.js"></script>
<script>
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>



<div id="body-link-poppers"><div id="body-link-popper-B1" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Practice guideline for the treatment of patients with schizophrenia, second edition.<div class="authors">Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J, American Psychiatric Association, Steering Committee on Practice Guidelines</div><div class="citation">Am J Psychiatry. 2004 Feb; 161(2 Suppl):1-56.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15000267/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B1">Ref list</a>]</p></div><div id="body-link-popper-B5" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Treatment of schizophrenia 1999. The expert consensus guideline series.<div class="authors"></div><div class="citation">J Clin Psychiatry. 1999; 60 Suppl 11():3-80.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10380713/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B5">Ref list</a>]</p></div><div id="body-link-popper-B4" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms.<div class="authors">Miller AL, Chiles JA, Chiles JK, Crismon ML, Rush AJ, Shon SP</div><div class="citation">J Clin Psychiatry. 1999 Oct; 60(10):649-57.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10549680/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B4">Ref list</a>]</p></div><div id="body-link-popper-B6" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="citation">Weiden PJ, Casey DE. "Polypharmacy": Combining antipsychotic medications in the treatment of schizophrenia. <span><span class="ref-journal">J Prac Psych and Behav Hlth. </span>1999;<span class="ref-vol">7</span>:229–233.</span></span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B6">Ref list</a>]</div><div id="body-link-popper-B7" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Combination antipsychotics: pros, cons, and questions.<div class="authors">Miller AL, Craig CS</div><div class="citation">Schizophr Bull. 2002; 28(1):105-9.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12047009/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B7">Ref list</a>]</p></div><div id="body-link-popper-B15" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Antipsychotic prescribing practices in the Veterans Healthcare Administration--New York metropolitan region.<div class="authors">Weissman EM</div><div class="citation">Schizophr Bull. 2002; 28(1):31-42.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12047020/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B15">Ref list</a>]</p></div><div id="body-link-popper-B8" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.<div class="authors">Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC</div><div class="citation">J Clin Psychiatry. 2004 Oct; 65(10):1377-88.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15491242/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B8">Ref list</a>]</p></div><div id="body-link-popper-B9" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Combination antipsychotic therapy in clinical practice.<div class="authors">Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N</div><div class="citation">Psychiatr Serv. 2003 Jan; 54(1):55-9.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12509667/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B9">Ref list</a>]</p></div><div id="body-link-popper-B14" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles.<div class="authors">Covell NH, Jackson CT, Evans AC, Essock SM</div><div class="citation">Schizophr Bull. 2002; 28(1):17-29.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12047017/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B14">Ref list</a>]</p></div><div id="body-link-popper-B16" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits.<div class="authors">Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher JP, Baldessarini RJ</div><div class="citation">Am J Psychiatry. 2004 Apr; 161(4):700-6.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15056517/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B16">Ref list</a>]</p></div><div id="body-link-popper-B19" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution.<div class="authors">Procyshyn RM, Kennedy NB, Tse G, Thompson B</div><div class="citation">Can J Psychiatry. 2001 May; 46(4):334-9.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11387789/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B19">Ref list</a>]</p></div><div id="body-link-popper-B20" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="citation">Yuzda MSK. Combination antipsychotics: what is the evidence? <span><span class="ref-journal">J Inform Pharamcother. </span>2000;<span class="ref-vol">2</span>:300–305.</span></span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B20">Ref list</a>]</div><div id="body-link-popper-B21" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations.<div class="authors">Freudenreich O, Goff DC</div><div class="citation">Acta Psychiatr Scand. 2002 Nov; 106(5):323-30.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12366465/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B21">Ref list</a>]</p></div><div id="body-link-popper-B11" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Multiple antipsychotic medication prescribing patterns.<div class="authors">Schumacher JE, Makela EH, Griffin HR</div><div class="citation">Ann Pharmacother. 2003 Jul-Aug; 37(7-8):951-5.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12841799/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B11">Ref list</a>]</p></div><div id="body-link-popper-B13" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Antipsychotic polypharmacy: squandering precious resources?<div class="authors">Stahl SM</div><div class="citation">J Clin Psychiatry. 2002 Feb; 63(2):93-4.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/11874226/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B13">Ref list</a>]</p></div><div id="body-link-popper-B22" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="citation">Meltzer HY, Kostakoglu A. Combining antipsychotics: is there evidence for efficacy? <span><span class="ref-journal">Psychiatric Times. </span>2000;<span class="ref-vol">17</span>:25–32.</span></span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B22">Ref list</a>]</div><div id="body-link-popper-B24" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Algorithm for treatment-refractory schizophrenia.<div class="authors">Koshino Y</div><div class="citation">Psychiatry Clin Neurosci. 1999 Oct; 53 Suppl():S9-13.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/10560891/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B24">Ref list</a>]</p></div><div id="body-link-popper-B10" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.<div class="authors">Loosbrock DL, Zhao Z, Johnstone BM, Morris LS</div><div class="citation">J Ment Health Policy Econ. 2003 Jun; 6(2):67-75.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/14578539/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B10">Ref list</a>]</p></div><div id="body-link-popper-B25" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Antipsychotic medication coprescribing in a large state hospital system.<div class="authors">Jaffe AB, Levine J</div><div class="citation">Pharmacoepidemiol Drug Saf. 2003 Jan-Feb; 12(1):41-8.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12616846/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B25">Ref list</a>]</p></div><div id="body-link-popper-B26" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Comparison of risperidone and olanzapine as used under "real-world" conditions in a state psychiatric hospital.<div class="authors">Advokat C, Dixon D, Schneider J, Comaty JE Jr</div><div class="citation">Prog Neuropsychopharmacol Biol Psychiatry. 2004 May; 28(3):487-95.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15093956/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B26">Ref list</a>]</p></div><div id="body-link-popper-B30" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="citation">Wang PF, Zhao Z. Comparison of olanzapine versus quetiapine in the treatment of hospitalized patients with schizophrenia. <span><span class="ref-journal">Value in Health. </span>2003;<span class="ref-vol">6</span>:355.</span></span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B30">Ref list</a>]</div><div id="body-link-popper-B18" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications.<div class="authors">Jerrell JM</div><div class="citation">Schizophr Bull. 2002; 28(4):589-605.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/12795493/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B18">Ref list</a>]</p></div><div id="body-link-popper-B28" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.<div class="authors">Gibson PJ, Damler R, Jackson EA, Wilder T, Ramsey JL</div><div class="citation">Value Health. 2004 Jan-Feb; 7(1):22-35.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/14720128/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B28">Ref list</a>]</p></div><div id="body-link-popper-B29" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="citation">Zhao Z, Tunis SL, Lage M. Medication treatment patterns following initiation on olanzapine versus risperidone. <span><span class="ref-journal">Clin Drug Invest. </span>2002;<span class="ref-vol">22</span>:741–749.</span></span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B29">Ref list</a>]</div><div id="body-link-popper-B27" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="citation">Correll CU, Kane JM, O'Shea D, Razi K, Malhotra AK. Antipsychotic polypharmacy inn the treatment of schizophrenia. <span><span class="ref-journal">Schizophr Res. </span>2003:37. doi: 10.1016/S0920-9964(03)80107-X.</span> <span class="nowrap ref crossref">[<a href="http://dx.doi.org/10.1016%2FS0920-9964(03)80107-X" target="pmc_ext" ref="reftype=other&amp;article-id=1156914&amp;issue-id=18178&amp;journal-id=62&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">Cross Ref</a>]</span></span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B27">Ref list</a>]</div><div id="body-link-popper-B31" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia.<div class="authors">Ascher-Svanum H, Zhu B, Faries D, Ernst FR</div><div class="citation">Ann Gen Hosp Psychiatry. 2004 Jun 2; 3(1):11.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15175112/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B31">Ref list</a>]</p></div><div id="body-link-popper-B32" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment.<div class="authors">Swanson JW, Swartz MS, Elbogen EB</div><div class="citation">Schizophr Bull. 2004; 30(1):3-20.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15176758/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B32">Ref list</a>]</p></div><div id="body-link-popper-B33" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="citation">Liang KY, Zeger SL. Longitudinal Data Analysis Using Generalized Linear Models. <span><span class="ref-journal">Biometrika. </span>1986;<span class="ref-vol">73</span>:13–22.</span></span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B33">Ref list</a>]</div><div id="body-link-popper-B34" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="citation">Chernick MR.  <span class="ref-journal">Bootstrap Methods: A Practicioner's Guide.</span> John Wiley &amp; Sons, Inc. New York, NY; 1999. </span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B34">Ref list</a>]</div><div id="body-link-popper-B35" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Dose response and dose equivalence of antipsychotics.<div class="authors">Davis JM, Chen N</div><div class="citation">J Clin Psychopharmacol. 2004 Apr; 24(2):192-208.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15206667/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#B35">Ref list</a>]</p></div></div>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <div class="breadcrumbs">You are here: 
            <span id="breadcrumb_text"><a href="http://www.ncbi.nlm.nih.gov/guide/">NCBI</a> &gt; <a href="http://www.ncbi.nlm.nih.gov/guide/literature/">Literature</a> &gt; <a href="http://www.ncbi.nlm.nih.gov/pmc/">PubMed Central (PMC)</a></span></div>
    <a id="help-desk-link" class="help_desk jig-ncbihelpwindow" target="_blank" href="http://www.ncbi.nlm.nih.gov/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.35&amp;Time=2016-06-23T14:11:33-04:00&amp;Host=ptpmc202">Write to the Help Desk</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="./PMC1156914_files/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="http://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="http://www.nlm.nih.gov/" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="http://www.nih.gov/" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="http://www.dhhs.gov/" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="http://www.usa.gov/" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            
            <a href="http://www.ncbi.nlm.nih.gov/About/disclaimer.html">Copyright</a> | <a href="http://www.ncbi.nlm.nih.gov/About/disclaimer.html#disclaimer">Disclaimer</a> |
            <a href="http://www.nlm.nih.gov/privacy.html" class="newdomain">Privacy</a> | 
            <a href="http://www.ncbi.nlm.nih.gov/guide/browsers/">Browsers</a> | <a href="http://www.nlm.nih.gov/accessibility.html">Accessibility</a> | <a href="http://www.ncbi.nlm.nih.gov/About/glance/contact_info.html">Contact</a>
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="http://www.ncbi.nlm.nih.gov/">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url"><a href="http://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
        </div>
    </div>
    <script type="text/javascript" src="./PMC1156914_files/InstrumentPageStarterJS.js"> </script>    
    <script type="text/javascript" src="./PMC1156914_files/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        <div style="display: none; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic">External link. Please review our <a href="http://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div><div class="ui-ncbiautocomplete-holder shadow ui-ncbiautocomplete-holder-clearfix" aria-live="assertive" style="display: none; top: 63.5938px; left: 408.188px; width: 670px; z-index: 1001;"><ul class="ui-ncbiautocomplete-options" role="listbox" aria-activedescendant="term"></ul><div class="ui-ncbiautocomplete-actions shadow" style="display: none;"><a class="ui-ncbiautocomplete-link-pref" style="display: none;">Preferences</a><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1156914/#" class="ui-ncbiautocomplete-link-off ui-ncbiautocomplete-link-pref-right" style="display: none;">Turn off</a></div></div></div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript>&lt;img alt="statistics" src="/stat?jsdisabled=true&amp;amp;ncbi_db=pmc&amp;amp;ncbi_pdid=article&amp;amp;ncbi_acc=&amp;amp;ncbi_domain=bmcpsyc&amp;amp;ncbi_report=record&amp;amp;ncbi_type=fulltext&amp;amp;ncbi_objectid=&amp;amp;ncbi_pcid=/articles/PMC1156914/&amp;amp;ncbi_app=pmc" /&gt;</noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- F4FC7E8376854741_0014SID /projects/PMC/PMCViewer@4.35 ptpmc202 v4.1.r480124 Mon, Sep 28 2015 02:46:19 -->

<script type="text/javascript" src="./PMC1156914_files/4065628.js" snapshot="pmc"></script>
<div class="ui-dialog ui-widget ui-widget-content ui-corner-all ui-front" tabindex="-1" role="dialog" aria-describedby="epubDialog" aria-labelledby="ui-id-1" style="display: none;"><div class="ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix"><span id="ui-id-1" class="ui-dialog-title">Making articles easier to read in PMC</span><button type="button" class="ui-button ui-widget ui-state-default ui-corner-all ui-button-icon-only ui-dialog-titlebar-close" role="button" title="Close"><span class="ui-button-icon-primary ui-icon ui-icon-closethick"></span><span class="ui-button-text">Close</span></button></div><div id="epubDialog" style="display: block;" class="ui-dialog-content ui-widget-content">  <p>We are experimenting with display styles that make it easier to read articles     in PMC.     Our first effort uses eBook readers, which have several "ease of reading"     features already built in.</p>  <p>These PMC articles are best viewed in the <em>iBooks     reader</em>. You may notice problems with the display of certain parts of an article     in other eReaders.</p>  <div class="ui-dialog-buttonpane ui-widget-content ui-helper-clearfix"><button id="cancelEpub" class="ui-state-default ui-corner-all">Cancel</button><button id="downloadEpub" style="float: left" class="ui-state-default ui-corner-all">Download article</button></div>          </div></div><ul class="print-log"><li></li></ul><div class="ui-ncbipopper-arrow-image ui-ncbipopper-arrow-right" style="display: none; top: -100px; left: -100px; opacity: 1;">&nbsp;</div><div class="ui-ncbipopper-arrow-image ui-ncbipopper-arrow-right" style="display: block; top: 566.953px; left: 893.453px; opacity: 1;">&nbsp;</div></body></html>